Methods for treating cancer
By using a bispecific anti-CTLA4/CD47 antibody combined with a PD-1/PD-L1 antibody, the limited efficacy of existing drugs targeting CTLA4 and CD47 has been addressed, achieving broader anti-tumor activity and lower toxicity, thus improving the safety and effectiveness of cancer treatment.
Patent Information
- Application Number
- CN202580014242.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-09-18
- Filing Date
- 2025-09-17
- Publication Date
- 2026-11-17
AI Technical Summary
Existing therapies targeting CTLA4 or CD47 have limited efficacy in cancer treatment and suffer from narrow therapeutic windows and immune-related adverse reactions, especially hematologic toxicity caused by anti-CTLA4 antibodies and dose-limiting hematologic toxicity caused by anti-CD47 antibodies.
The anti-CTLA4/CD47 bispecific antibody promotes TIL-Treg depletion and enhances the immune response by specifically binding to CTLA4 and CD47. It also enhances anti-tumor activity and reduces immune-related adverse reactions and hematologic toxicity by binding to anti-PD-1 or anti-PD-L1 antibodies.
It achieved broader antitumor activity, reduced immune-related adverse events and hematologic toxicity, and improved the safety and efficacy of treatment.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Related applications
[0001] This application claims priority to PCT patent application number PCT / CN2024 / 119472, filed on September 18, 2024, the entire contents of which are incorporated herein by reference. References to sequence lists submitted electronically
[0002] This application incorporates by reference a sequence list, which is an XML file entitled “720A009CN02 PWNCN260791-MO_SL.xml”, created on August 7, 2026, and is 122,938 bytes in size. Technical Field
[0003] This invention relates to molecular biology and cell biology. This document provides a method for treating cancer in a subject of need, comprising administering a therapeutically effective amount of an anti-CTLA4 / CD47 bispecific antibody to the subject. Background Technology
[0004] Immune checkpoint inhibitors have emerged as a promising class of molecules for therapeutic development (e.g., molecules targeting PD-1, Tim-3, and CTLA4). Despite Keytruda... ® and Opdivo ® While checkpoint inhibitors and other inhibitors have achieved success, current treatments targeting CTLA4 or CD47 have only seen limited success (primarily in melanoma) due to their narrow therapeutic window. Therefore, there is an urgent unmet need for alternative cancer treatments, particularly those targeting CTLA4 and / or CD47, with improved efficacy and safety. The approach provided in this disclosure addresses this need and offers relevant advantages. Summary of the Invention
[0005] This article provides a method for treating cancer in a subject with this need, comprising administering to the subject a therapeutically effective amount of an anti-CTLA4 / CD47 bispecific antibody; wherein the bispecific antibody comprises: (i) a light chain variable domain (VL) and a heavy chain variable domain (VH) having amino acid sequences that are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, respectively, identical to those of SEQ ID NOs:7 and 8, and the VL / VH specifically binds to human CTLA4; and (ii) a CD47 binding domain having amino acid sequences that are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5%, identical to those of SEQ ID NO:9; and wherein the bispecific antibody is administered at a dose of about 0.1 mg / kg to about 25.0 mg / kg of the subject's body weight. In some embodiments, (i) the VL and VH have amino acid sequences of SEQ ID NOs:7 and 8, respectively; and (ii) the CD47 binding domain has an amino acid sequence of SEQ ID NO:9.
[0006] In some embodiments, the bispecific antibody comprises: (1) a first peptide chain (C1) including the VL and a light chain constant region (CL); (2) a second peptide chain (C2) including the VH and a heavy chain constant region (CH); and (3) a third peptide chain (C3) including the CD47 binding domain and an Fc region. In some embodiments, (1) the amino acid sequence of C1 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:51; (2) the amino acid sequence of C2 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:52; and (3) the amino acid sequence of C3 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:53. In some embodiments, C1, C2 and C3 have amino acid sequences of SEQ ID NOs:51, 52 and 53, respectively.
[0007] In some embodiments, the bispecific antibody is administered at a dose selected from the group consisting of about 0.1 mg / kg, about 0.5 mg / kg, about 1.0 mg / kg, about 2.0 mg / kg, about 4.0 mg / kg, about 8.0 mg / kg, about 10.0 mg / kg, about 12.0 mg / kg, about 15.0 mg / kg, about 20.0 mg / kg, and about 25.0 mg / kg. In some embodiments, more than one dose of the bispecific antibody is administered. In some embodiments, at least 4, at least 8, at least 12, at least 16, at least 20, at least 24, at least 28, or at least 32 doses of the bispecific antibody are administered. In some embodiments, the bispecific antibody is administered at a dosing interval of about once every 3 weeks. In some embodiments, the bispecific antibody is administered in liquid form. In some embodiments, the bispecific antibody is administered via intravenous infusion. In some embodiments, a single dose of the bispecific antibody is administered over 60 to 120 minutes. In some embodiments, a single dose of the bispecific antibody is administered over approximately 90 minutes.
[0008] In some embodiments, the bispecific antibody is administered in combination with an anti-PD-1 or anti-PD-L1 antibody. In some embodiments, the anti-PD-1 or anti-PD-L1 antibody is administered simultaneously with the bispecific antibody. In some embodiments, the anti-PD-1 or anti-PD-L1 antibody is patelimab. In some embodiments, the anti-PD-1 or anti-PD-L1 antibody is pembrolizumab. In some embodiments, the patelimab or pembrolizumab is administered at a dose of approximately 200 mg. In some embodiments, the patelimab or pembrolizumab is administered at a frequency of approximately once every 3 weeks.
[0009] This document provides a method for treating cancer in a subject with this need, comprising administering to the subject a therapeutically effective amount of the anti-CTLA4 / CD47 bispecific antibody disclosed herein. In some embodiments, the cancer is a hot tumor. In some embodiments, the cancer is a cold tumor. In some embodiments, the cancer is infiltrated by immune cells. In some embodiments, the cancer is advanced or metastatic. In some embodiments, the cancer is relapsed, resistant, or refractory. In some embodiments, the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy.
[0010] In some embodiments, the subject is a human being. In some embodiments, the subject has received anti-PD-1 / PD-L1 treatment.
[0011] In some embodiments, the methods provided herein (1) exhaust tumor-infiltrating lymphocytes (TILs)-regulatory T cells (Treg cells) or Treg cells in the tumor microenvironment (TME); (2) increase cytokine levels in the TME; (3) enhance T cell proliferation and / or activity against said cancer; (4) enhance macrophage-mediated phagocytosis; (5) enhance dendritic cell-mediated antigen presentation; or any combination of (1)-(5). In some embodiments, the methods provided herein (1) selectively eliminate CTLA4 and CD47 positive cells by antibody-dependent cell-mediated cytotoxicity (ADCC); (2) have a low risk of triggering immune-related adverse events (irAEs); (3) have a low risk of triggering cytokine release syndrome (CRS); or (4) have reduced hematologic toxicity; or any combination of (1) to (4). Attached Figure Description
[0012] Figure 1 Results are provided in a humanized syngeneic mouse colon cancer model of the target gene (MC38-hCD47 model inoculated into hCTLA4xhCD47xhSIRPα HuGEMM mice), demonstrating the in vivo antitumor activity of HX044. Tumor growth was measured twice weekly and is expressed as mean tumor size ± SEM for each group. Ipilimumab and SIRPα-Fc were used as reference antibodies / proteins.
[0013] Figure 2 Results are provided in a humanized syngeneic mouse melanoma model of the target gene (inoculated with B16F10-hCD47 in hCTLA4xhCD47xhSIRPαHuGEMM mice) demonstrating the in vivo antitumor activity of HX044. Tumor growth was measured twice weekly and is expressed as mean tumor size ± SEM for each group. Ipilimumab and SIRPα-Fc were used as reference antibodies / proteins.
[0014] Figure 3 Flow cytometry results are provided, showing tumor-infiltrating lymphocytes (TILs) collected from mice at the end of treatment in a syngeneic mouse model (a B16F10-hCD47 model inoculated into hCTLA4xhCD47xhSIRPα mice). Ipilimumab analogues and SIRPα-Fc were used as reference antibodies / proteins.
[0015] Figure 4 Flow cytometry results are provided, showing the effect of HX044 treatment on lymphocyte composition in a syngeneic mouse model (hCTLA4 x hCD47 x hSIRPα HuGeMM C57BL / 6J mice). Ipilimumab analogues and SIRPα-Fc were used as reference antibodies / proteins.
[0016] Figure 5 Results of an in vivo study are provided, demonstrating the effect of combining HX044 with an anti-PD-1 antibody in C57BL / 6 mice carrying MC38 tumors.
[0017] Figure 6 A schematic overview is provided, illustrating the Phase I and Phase IIa trial designs.
[0018] Figure 7 A schematic overview is provided, illustrating the accelerated titration stage and the conventional 3+3 stage. Detailed Implementation
[0019] This document provides a method for treating cancer in a subject with this need, comprising administering to the subject a therapeutically effective amount of an anti-CTLA4 / CD47 bispecific antibody. This document also discloses a method for treating cancer in a subject with this need, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an anti-CTLA4 / CD47 bispecific antibody. This document also discloses combination therapy with anti-PD1 or anti-PD-L1 antibodies.
[0020] Cytotoxic T-lymphocyte-associated protein-4 (CTLA4) is a classic immune checkpoint that inhibits T-cell function by blocking the interaction between the co-stimulatory receptors B7-1 (CD80) / B7-2 (CD86) on antigen-presenting cells (APCs) and the co-activator CD28 on T cells. CTLA4 plays a role in tumor-infiltrating (TIL) T cells. reg It is expressed at a high constitutive level in the tumor, exceeding the expression levels in normal blood compartments and also higher than that of activated CD8 in the tumor microenvironment (TME). + effector T cells (T cells) eff The expression level of CTLA4 in APCs is also known to be blocked by anti-CTLA4 antibodies, which block the binding of CTLA4 to its ligands CD80 / CD86 on APCs, thereby leading to the release of a second signal mediated by CD80 / CD86 and reactivation of effector T cells. On the other hand, ADCC effector and / or macrophage-mediated tumor-infiltrating regulatory T cells (T cells) are also affected. reg The depletion of CTLA4 and its remodeling of the innate immune system via binding to the Fcγ receptor (FcγR) in the TME have also been shown to contribute to the antitumor activity of CTLA4. However, anti-CTLA4 antibodies have not yet achieved widespread success in cancer treatment due to their narrow therapeutic window, primarily attributed to a high rate of systemic immune-related adverse events (irAEs).
[0021] CD47 is a "don't eat me" receptor that is overexpressed in many human cancers. CD47, along with its ligands on the surface of phagocytes, including macrophages and dendritic cells (DCs), constitutes a key innate and adaptive immune checkpoint protein and is a promising target for immunotherapy. Targeting CD47 with anti-CD47 antibodies or CD47-trap (i.e., signal regulatory protein α or SIRPα) has been extensively tested, but has not yet shown clinical success, again due to its narrow therapeutic window. On the other hand, due to the widespread expression of CD47 on megakaryocytes and erythrocytes, targeting CD47 has been found to be associated with dose-limiting hematologic toxicities (DLTs), such as anemia and thrombocytopenia.
[0022] This article discloses the role of anti-hCTLA4 / hCD47 bispecific antibodies in promoting TIL-T. reg It exhibits synergistic activity in terms of depletion and demonstrates superior antitumor activity compared to agents targeting either hCTLA4 or hCD47, with very limited hematologic toxicity and immune-related adverse events (irAEs). Due to its larger therapeutic window than single-target agents, the dual-targeting bsAbs disclosed herein could be used as a safer and more effective anticancer therapeutic agent.
[0023] Programmed cell death 1 (PD-1), also known as DCD1, SystemicLupus Erythematosus Susceptibility 2, Protein PD-1, HPD-1, CD279 Antigen; HPD-L; HSLE1, or SLEB2, is a cell surface receptor belonging to the CD28 receptor family and expressed on T cells and pro-B cells. PD-1 functions as an immune checkpoint, playing a crucial role in downregulating the immune system by inhibiting T cell activation, thereby reducing autoimmunity and promoting self-tolerance. PD-1 is known to bind two ligands: programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). PD-L1 is a member of the B7 family of proteins, which play a role in suppressing immune responses during specific events. PD-L1 is expressed on a variety of cells, including normal tissues, immune cells, and various types of cancer cells. PD-L1 is widely recognized for its role in tumor immune escape. High expression of PD-L1 on tumors is often associated with poor prognosis because it allows cancer cells to evade immune surveillance. The binding of PD-L1 to PD-1 transmits inhibitory signals, thereby reducing the proliferation of PD-1-expressing T cells. PD-L1 is expressed by a variety of cancer cells, and its expression is thought to at least partially contribute to a weakened immune response against cancer cells. Drugs that block the PD-1 / PD-L1 interaction are used as immune checkpoint inhibitors in cancer immunotherapy. Various antibodies that block PD-1 or PD-L1 activity activate the immune system to attack tumors and have therefore been successfully used to treat certain types of cancer.
[0024] Before further describing this disclosure, it should be understood that this disclosure is not limited to the specific embodiments set forth herein, and it should also be understood that the terminology used herein is intended to describe specific embodiments and is not intended to constitute a limitation. Terminology Definition
[0025] Unless otherwise defined herein, scientific and technical terms used in this disclosure shall have the meanings commonly understood by one of ordinary skill in the art. Furthermore, unless the context requires otherwise, singular terms shall include plural forms, and plural terms shall include singular forms. Generally, the nomenclature and techniques described herein relating to cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization are well-known and commonly used nomenclature and techniques in the art.
[0026] The term “a” or “an” refers to one or more species of the entity; for example, “an antibody” should be understood to mean one or more antibodies.
[0027] The term “and / or” as used herein should be considered as a specific disclosure of each of the two features or components, with or without the other. Therefore, the term “and / or” as used in phrases such as “A and / or B” is intended to include “A and B”, “A or B”, “A” (alone), and “B” (alone). Similarly, the term “and / or” as used in phrases such as “A, B, and / or C” is intended to cover each of the following: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0028] As used herein, the term "about" is used to indicate a value that includes inherent error variations in the apparatus used to determine the value, error variations in the method used to determine the value, or variations existing among the study subjects. The term "about" encompasses the precise value. In some embodiments, "about" means within ±10% of a given value or range. In some embodiments, "about" means a variation of ±5%, ±4%, ±3%, ±2%, ±1%, ±0.5%, ±0.2%, or ±0.1% of the value referred to by "about". In some embodiments, "about" means a variation of ±1%, ±0.5%, ±0.2%, or ±0.1% of the value referred to by "about".
[0029] The terms “peptide chain,” “peptide,” “polypeptide,” “protein,” and their grammatical equivalents, used interchangeably in this document, refer to an amino acid polymer of any length, which may be linear or branched. It may include non-natural or modified amino acids, or be interrupted by non-amino acid molecules. Polypeptides, peptides, polypeptide chains, or proteins may also be modified, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other treatment or modification.
[0030] As used herein and as understood in the art, an "antibody" refers to an immunoglobulin molecule that recognizes and specifically binds to a target (e.g., a protein) via at least one antigen-binding fragment, typically located within a variable region of the immunoglobulin molecule. Antibodies can have a variety of different types and structures. For example, an antibody can be a polyclonal antibody, monoclonal antibody, multispecific antibody, bispecific antibody, monospecific antibody, monovalent antibody, or any other modified immunoglobulin molecule containing an antigen-binding site. Antibodies also include, but are not limited to, mouse antibodies, camel antibodies, chimeric antibodies, humanized antibodies, and human antibodies. An antibody can be any of the five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or a subclass (isotype) thereof (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), based on the identity of their heavy chain constant domains, referred to as α, δ, ε, γ, and μ, respectively. Unless otherwise expressly indicated, the term "antibody" as used herein includes the "antigen-binding fragment" of a complete antibody. As used herein, the term "antigen-binding fragment" refers to a peptide fragment that specifically binds to an antigen, which may be derived from an antibody, receptor, or any naturally occurring or engineered binding domain, and retains its specific binding to its target antigen. In some embodiments, such fragments contain the antigen-determining variable region of the complete antibody. Examples of antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv, linear antibodies, single-chain antibody molecules (e.g., scFv), heavy chain antibodies (HCAbs), light chain antibodies (LCAbs), disulfide-linked scFv (dsscFv), dibodies, tribodies, tetrabodies, minibodies, bivariate domain antibodies (DVD), single variable domain antibodies (sdAbs; e.g., camelid antibodies, alpaca antibodies), and the single variable domain (VHH) of heavy chain antibodies. The term also encompasses engineered or naturally occurring non-immunoglobulin binding domains derived from receptors that specifically recognize the same target. For example, antigen-binding fragments targeting CD47 include extracellular domains of signal regulatory protein α (SIRPα)—such as the N-terminal Ig-like V-set domain (D1), the D1–D2 tandem domain, or variants, isoforms, orthologs, and fragments thereof—that specifically bind to CD47.
[0031] As used herein and as understood in the art, a "bispecific" antibody refers to an artificial hybrid antibody having two different antigen-binding fragments. These two different antigen-binding fragments specifically bind to two different target antigens. Bispecific antibodies can be formed from antibody fragments. In this document, an anti-CTLA4 / CD47 bispecific antibody refers to a bispecific antibody that specifically binds to both CTLA4 and CD47.
[0032] The structure of immunoglobulins has been well characterized (see, for example, Chapter 7 of Fundamental Immunology (Paul, W., ed., 2nd ed., Raven Press, New York (1989))). Typically, immunoglobulins consist of two pairs of polypeptide chains, one pair of light (L; low molecular weight) chains and one pair of heavy (H; high molecular weight) chains, all four chains being interconnected by disulfide bonds.
[0033] Each light chain of an immunoglobulin typically comprises a variable region (“VL region”) and a constant region (“CL region”). There are two distinct types of light chains, designated κ (kappa) or λ (lambda) based on the amino acid sequence of the CL region. The amino acid sequence of the CL region is well-known in the art.
[0034] Each heavy chain typically comprises a variable region (“VH region”) and a constant region (“CH region”). Based on the amino acid sequence, the VH region can be one of five different types, referred to as α (alpha), δ (delta), ε (epsilon), γ (gamma), and μ (mu). When bound to a light chain, these different types of heavy chains produce five known classes of antibodies: IgA, IgD, IgE, IgG, and IgM. IgG has four subclasses: IgG1, IgG2, IgG3, and IgG4. The amino acid sequences of the CH regions of different antibody classes are well known in the art.
[0035] The CH region of an immunoglobulin contains more than one domain. For example, the CH region of an IgG antibody consists of three domains: heavy chain constant domain 1 (CH1), heavy chain constant domain 2 (CH2), and heavy chain constant domain 3 (CH3). The highly flexible region located between the CH1 and CH2 domains is called the "hinge region." Disulfide bonds in the hinge region constitute part of the interaction between the two heavy chains in an immunoglobulin. The "Fc region" refers to the C-terminal region of the immunoglobulin heavy chain, which contains at least a portion of the constant region. In the IgG, IgA, and IgD isotypes, the Fc region consists of the CH2 and CH3 domains; the Fc regions of IgM and IgE contain three heavy chain constant domains (CH domains 2–4). The amino acid sequences of the Fc regions of human IgG, IgA, IgD, IgM, and IgE, as well as the IgG1, IgG2, IgG3, and IgG4 isotypes, are known to those skilled in the art. The native Fc region can be modified. Modifications to the Fc region are further described below. In some embodiments, the bispecific antibodies provided herein may comprise paired Fc domains containing paired different modifications to promote their association with each other rather than forming homodimers.
[0036] Unless otherwise stated or the context contradicts, references to amino acid positions in constant regions are made according to EU numbers (Edelman et al., PNAS. 1969; 63:78-85, Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition. 1991 NIH Publication No. 91-3242). An exemplary list of amino acid sequences for the constant domains / regions of human IgG antibodies is provided below. Exemplary variants are also included, and further variants are disclosed in the following sections.
[0037] Table 1. Constant regions / domains of natural human IgG.
[0038] The term "variable region" refers to a portion of the light or heavy chain of an immunoglobulin, typically located at the amino terminus of the light or heavy chain, and is responsible for the binding and specificity of each particular antibody to its specific antigen. The variable region of the light chain is called the "light chain variable region" or "VL region," and it includes at least one, usually a "light chain variable domain" or "VL." The variable region of the heavy chain is called the "heavy chain variable region" or "VH region," and it includes at least one, usually a "heavy chain variable domain" or "VH." Variable domains vary widely in sequence between different antibodies. A "VL / VH pair" can associate with each other to form a binding site that specifically binds to a target antigen or epitope.
[0039] The VH and VL regions can be further subdivided into hypervariable regions (or hypervariable regions that may be highly variable in sequence and / or in the form of structurally defined loops), also known as complementarity-determining regions (CDRs), interspersed with more conserved regions called frame regions (FRs). Sequence variability is concentrated in the CDRs, while the less variable portions of the variable domains are called frame regions (FRs). The CDRs of the light and heavy chains are primarily responsible for antibody-antigen interactions. Each VH and VL typically consists of three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (see also Chothia and Lesk, J Mol Biol 1987;196:901-17).
[0040] A CDR (Constant Variable Domain) refers to one of the three hypervariable regions (H1, H2, or H3) within the non-framework region of the VH β-sheet framework of an immunoglobulin (Ig or antibody), or one of the three hypervariable regions (L1, L2, or L3) within the non-framework region of the VL β-sheet framework of an antibody. CDR regions are well known to those skilled in the art and have been defined using various methods and systems. These systems and / or definitions have been developed and refined over many years, including Kabat, Chothia, IMGT, AbM, and Contact. For example, Kabat defines the region with the highest variability within the variable (V) domain of an antibody (Kabat et al., J. Biol. Chem. 252:6609-6616 (1977); Kabat, Adv. Prot. Chem. 32: 1-75 (1978)). Software programs (e.g., abYsis) for analyzing antibody sequences and determining CDRs are known and available to those skilled in the art.
[0041] As used herein, the term "humanized antibody" refers to a form of non-human (e.g., mouse) antibody that is a specific immunoglobulin chain, chimeric immunoglobulin, or fragment thereof containing minimal non-human sequences. Typically, humanized antibodies are human immunoglobulins. In some cases, the variable region residues of a human immunoglobulin are replaced with corresponding residues from an antibody derived from a non-human species. In some cases, residues of CDRs are replaced with CDR residues from non-human species (e.g., mice, rats, hamsters, camels, rabbits, goats, sharks, alpacas) possessing the desired specificity, affinity, and / or binding capacity. Humanized antibodies can be further modified by further substituting additional residues within the variable region and / or within the replaced non-human residues to refine and optimize antibody specificity, affinity, and / or binding capacity. As used herein, the term "human antibody" refers to an antibody produced by humans, or an antibody having an amino acid sequence corresponding to that of a human-produced antibody and prepared using any technique known in the art.
[0042] As used herein, the term "variant," when referring to a protein or polypeptide ("reference protein" or "reference polypeptide") having specific sequence characteristics, means a different protein or polypeptide compared to the reference protein or reference polypeptide with one or more (e.g., about 1 to about 25, about 1 to about 20, about 1 to about 15, about 1 to about 10, or about 1 to about 5) amino acid substitutions, deletions, and / or additions. Changes to the amino acid sequence can be amino acid substitutions. Changes to the amino acid sequence can be conserved amino acid substitutions. Functional fragments or functional variants of the protein or polypeptide retain the basic structural and functional properties of the reference protein or reference polypeptide.
[0043] As used herein, the term "specific binding" refers to a more frequent, faster, longer-lasting, or more affinity interaction between a polypeptide or molecule and an epitope, protein, or target molecule, or some combination thereof, relative to interactions with surrogate substances (including related and unrelated proteins). Binding groups (e.g., antibodies) that specifically bind to target molecules (e.g., antigens) can be identified by, for example, immunoassays, ELISA, biolayer interference (“BLI”), SPR (e.g., Biacore), or other techniques known to those skilled in the art. Typically, a specific response is at least twice the background signal or noise, and can exceed 10 times the background. For a discussion of antibody specificity, see, for example, Paul, ed., 1989. Fundamental Immunology Second Edition Raven Press, New York, pp. 332-336. In some embodiments, "specific binding" refers, for example, to binding groups at a Kc of about 0.1 mM or lower. D Binding to a molecular target. In some embodiments, "specific binding" refers to the peptide or molecule binding at a concentration of approximately 10 µM or less, or approximately 1 µM or less, of K+. DBinding to the target. In some implementations, "specific binding" refers to the peptide or molecule binding at a K+ level of about 0.1 µM or less, about 0.01 µM or less, or about 1 nM or less. D Target binding. Due to sequence identity between homologous proteins in different species, specific binding may include peptides or molecules that recognize proteins or targets in more than one species. Similarly, due to homology in certain regions of peptide sequences of different proteins, specific binding may include peptides or molecules that recognize more than one protein or target.
[0044] The term "binding affinity" as used in this article generally refers to the strength of the sum of all non-covalent interactions between the binding group and the target molecule (e.g., antigen). The binding of the binding group to the target molecule is a reversible process, and the affinity of this binding is typically expressed as a function of the equilibrium dissociation constant (K0). D ) indicates. K D dissociation rate (k) off or k d ) and association rate (k on or k a The ratio of ) to. Combined with the pair K D The lower the value, the higher the affinity. Various methods for measuring binding affinity are known in the art, any of which can be used for the purposes of this disclosure. Specific exemplary embodiments include the following. In some embodiments, “K…” D The "KD value" or "KD value" can be measured by methods known in the art, such as by combination determination. D It can be measured in radiolabeled antigen binding assays (RIA) (Chen, et al., (1999) J. Mol Biol 293:865-881). K D or K D The value can also be measured using biological layer interferometry (BLI), for example using the Gator system (Probe Life) or the Octet-96 system (Sartorius AG). K D or K D The value can also be measured using Biacore's surface plasmon resonance (SPR) assay, for example using the BIAcore™-2000 or BIAcore™-3000 (BIAcore, Inc., Piscataway, NJ). Binding affinity can also be measured using EC. 50 To quantify, EC 50 It is the ligand concentration when half of the target is in the bound state during the binding assay.
[0045] As used herein, the terms "CD47 positive" or "CD47+" in the context of cells refer to cells with detectable CD47 expression. In some embodiments, the cells have detectable CD47 expression on their surface. As used herein, the terms "CD47 positive" or "CD47+" in the context of cancer or tumors refer to cancer or tumors with cells exhibiting detectable CD47 expression. As used herein, the terms "CTLA4 positive" or "CTLA4+" in the context of cells refer to cells with detectable CTLA4 expression. In some embodiments, the cells have detectable CTLA4 expression on their surface. As used herein, the terms "CTLA4 positive" or "CTLA4+" in the context of cancer or tumors refer to cancer or tumors with cells exhibiting detectable CTLA4 expression. Those skilled in the art can readily determine whether a cancer or tumor expresses CD47 and / or CTLA4 using any method known and available in the art, including, for example, immunohistochemistry (IHC), immunocytochemistry (ICC), enzyme-linked immunosorbent assay (ELISA), flow cytometry (FACS), etc.
[0046] As used herein, the terms “identical,” “percentage identity,” and their grammatical equivalents, in the context of two or more polynucleotides or peptides, mean that two or more sequences or subsequences are identical, or have a specified percentage of identical nucleotide or amino acid residues, when compared and aligned (with gaps introduced where necessary) to obtain maximum correspondence, without considering any conserved amino acid substitutions as part of sequence identity. Percentage identity can be measured using sequence comparison software or algorithms, or by visual inspection. Various algorithms and software known in the art can be used to obtain amino acid or nucleotide sequence alignments. These include, but are not limited to, BLAST, ALIGN, Megalign, BestFit, GCG Wisconsin Package, and variants thereof. In some embodiments, the two polynucleotides or peptides provided herein are substantially identical, i.e., they have at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, and in some embodiments at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% nucleotide or amino acid residue identity when compared and aligned to obtain maximum correspondence, which is measured by sequence comparison algorithms or by visual inspection. In some embodiments, the identity resides in a region of an amino acid sequence, the length of which is at least about 10 residues, at least about 20 residues, at least about 40-60 residues, at least about 60-80 residues, or any integer value between thereof. In some embodiments, the identity resides in a longer region than 60-80 residues, for example, at least about 80-100 residues, and in some embodiments, the compared sequences are substantially identical in their entire length, such as the coding region of a target protein or antibody. In some embodiments, the identity resides in a region of a nucleotide sequence, the length of which is at least about 10 bases, at least about 20 bases, at least about 40-60 bases, at least about 60-80 bases, or any integer value between thereof. In some embodiments, the identity resides in a longer region than 60-80 bases, for example, at least about 80-1000 bases or more, and in some embodiments, the compared sequences are substantially identical in their entire length, such as nucleotide sequences encoding a protein of interest.
[0047] "Isolated" polypeptides, peptides, proteins, antibodies, polynucleotides, carriers, cells, or compositions refer to polypeptides, peptides, proteins, antibodies, polynucleotides, carriers, cells, or compositions that exist in a form not found in nature. Isolated polypeptides, peptides, proteins, antibodies, polynucleotides, carriers, cells, or compositions include those that have been purified to the point that they no longer exist in their naturally occurring form. In some embodiments, the isolated polypeptides, peptides, proteins, antibodies, polynucleotides, carriers, cells, or compositions are substantially pure.
[0048] As used herein, the term "treatment" and its grammatical equivalents, when relating to a disease or condition, or a subject suffering from a disease or condition, refer to behaviors, interventions, and / or measures that inhibit, eliminate, reduce, and / or improve symptoms, severity, and / or frequency of symptoms associated with the treated disease or disorder. Treatment for osteoporosis can inhibit, eliminate, reduce, or improve symptoms associated with osteoporosis. These symptoms primarily include bone loss, decreased bone density, and increased risk of fracture, and the treatment aims to slow the rate of bone loss, strengthen bones, and reduce the likelihood of fractures.
[0049] As used herein, the term "administration" and its grammatical equivalents refer to the act of delivering, or facilitating the delivery of, a therapeutic agent or pharmaceutical composition to a subject by the methods described herein or other methods known in the art. The therapeutic agent may be a compound, peptide, antibody, cell, or cell population. Administration of a therapeutic agent or pharmaceutical composition includes prescribing for delivery of the therapeutic agent or pharmaceutical composition to a subject. Exemplary forms of administration include oral dosage forms, such as tablets, capsules, syrups, and suspensions; injectable dosage forms, such as intravenous (IV), intramuscular (IM), or intraperitoneal (IP); transdermal dosage forms, including creams, gels, powders, or patches; buccal mucosal dosage forms; inhaled powders, sprays, suspensions, and rectal suppositories.
[0050] As used herein, the terms "effective amount," "therapeutic effective amount," and their grammatical equivalents refer to the dosage of an agent administered to a subject, wherein the agent may be administered alone or as part of a pharmaceutical composition, and may be administered in a single dose or as part of a series of doses, and when administered to the subject, the dosage is capable of producing any detectable positive effect on any symptom, aspect, or characteristic of a disease, disorder, or condition. The therapeutic effective amount can be determined by measuring the relevant physiological effects. The exact amount required varies from subject to subject, depending on the subject's age, weight and general condition, the severity of the condition being treated, the clinician's judgment, etc. In any individual case, an appropriate "effective amount" can be determined by a person skilled in the art through routine experiments.
[0051] As used herein, the term "combination" or its grammatical equivalents, when relating to treatment or therapy, refers to the use of multiple therapeutic agents or methods to treat a single disease or condition. The treatment may include drugs, radiation therapy, surgery, or other methods that may be administered simultaneously or sequentially over a longer period, and treatment cycles may overlap. Combination therapy can provide a variety of therapeutic benefits. In some embodiments, the combination of different therapies can work synergistically. For example, a drug can alter the disease state or biological environment in a way that enhances the effectiveness of another drug or treatment. In some embodiments, combination therapy can help reduce overall toxicity relative to monotherapy by allowing for a reduction in the dosage of each agent or by more effectively managing side effects. In some embodiments, combination therapy can prevent or delay the development of drug resistance. Using multiple therapies targeting different pathways or mechanisms can make a disease more difficult to adapt to and develop drug resistance.
[0052] When administering combination therapy to a subject, two, three, or more treatment modalities may be administered "simultaneously" or "sequentially." "Simultaneous" administration, as used herein, means that two therapies are administered within the same or overlapping timeframe. The two therapies administered simultaneously may begin at the same time or not at the same time, and may end at the same time or not at the same time. Conversely, "sequential" administration means that a second therapy is administered after the first therapy has ended, with no overlapping treatment periods.
[0053] As used herein, the term "subject" refers to any animal (e.g., a mammal), including but not limited to humans, non-human primates, canines, felines, rodents, etc., that will serve as a recipient of a specific treatment. Mammals include, but are not limited to, farm animals, sporting animals, pets, primates, horses, dogs, cats, mice, and rats. Human subjects requiring this treatment may be human subjects who have, are at risk of having, or are suspected of having a disease. Subjects with a disease can be identified through routine medical examinations, such as physical examination, laboratory tests, organ function tests, CT scans, or ultrasound examinations. Subjects suspected of having any such disease may exhibit one or more symptoms of that disease. Subjects at risk of having the disease may be subjects who have one or more risk factors for the disease. Subjects may be human. Subjects may have a specific disease or condition.
[0054] Scope: In this disclosure, various aspects of the invention may be presented in a scope format. It should be understood that the description in scope format is for convenience and brevity purposes only and should not be construed as a rigid limitation on the scope of the invention. Therefore, a description of a scope should be considered as having specifically disclosed all possible sub-scopes within that scope as well as individual numerical values. For example, a description of a scope such as 1 to 6 should be considered as having specifically disclosed sub-scopes such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as individual numbers within that scope, such as 1, 2, 2.7, 3, 4, 5, 5.3, and 6. The above principle applies regardless of the width of the scope.
[0055] Exemplary genes and peptides are described herein with reference to GenBank numbers, GI numbers, and / or SEQ ID NOS. It should be understood that those skilled in the art can readily identify homologous sequences by referring to the sequence sources (including, but not limited to, GenBank (ncbi.nlm.nih.gov / genbank / ) and EMBL (embl.org / )). Composition
[0056] This document provides compositions comprising the anti-CTLA4 / CD47 bispecific antibody disclosed herein. In some embodiments, this document provides pharmaceutical compositions comprising a therapeutically effective amount of the bispecific antibody disclosed herein and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical compositions are intended for the treatment of cancer.
[0057] In some embodiments, the pharmaceutical compositions provided herein comprise a bispecific antibody comprising: (i) a light chain variable domain (VL) and a heavy chain variable domain (VH) having an amino acid sequence identity of at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% with respect to SEQ ID NOs:7 and 8, respectively, and said VL / VH specifically binds to human CTLA4; and (ii) a CD47 binding domain having an amino acid sequence identity of at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% with respect to SEQ ID NO:9. In some embodiments, the pharmaceutical compositions provided herein comprise a bispecific antibody comprising: (i) a light chain variable domain (VL) and a heavy chain variable domain (VH) having amino acid sequences of SEQ ID NOs:7 and 8, respectively, and the VL / VH pair specifically binds to human CTLA4; and (ii) a CD47 binding domain having an amino acid sequence of SEQ ID NO:9.
[0058] Table 2A: VL / VH and CDRs of exemplary anti-CTLA4 antibodies
[0059] Table 2B: SIRPα domains
[0060] In some embodiments, the pharmaceutical composition provided herein comprises a bispecific antibody comprising: (1) a first peptide chain (C1) comprising VL, the amino acid sequence of which has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:51; (2) a second peptide chain (C2) comprising VH, the amino acid sequence of which has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:52; and (3) a third peptide chain (C3) comprising a CD47 binding domain, the amino acid sequence of which has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:53. In some embodiments, the pharmaceutical compositions provided herein comprise a bispecific antibody comprising: (1) a first peptide chain (C1) comprising a VL having the amino acid sequence of SEQ ID NO:51; (2) a second peptide chain (C2) comprising a VH having the amino acid sequence of SEQ ID NO:52; and (3) a third peptide chain (C3) comprising a CD47-binding domain having the amino acid sequence of SEQ ID NO:53, namely HX044. In some embodiments, the bispecific antibody is a monoclonal antibody. In some embodiments, the bispecific antibody is isolated. In some embodiments, the bispecific antibody is substantially pure. Methods for preparing bispecific antibodies are well known in the art.
[0061] Table 3: Amino acid sequence of the peptide chain of HX044
[0062] This document also provides compositions comprising anti-PD-1 or PD-L1 antibodies, which can be used in combination with the bispecific antibodies disclosed herein for the treatment of cancer. In some embodiments, this document provides pharmaceutical compositions comprising a therapeutically effective amount of the bispecific antibody disclosed herein, an anti-PD-1 or PD-L1 antibody, and a pharmaceutically acceptable carrier.
[0063] In some embodiments, the anti-PD-1 or PD-L1 antibody may be nivolumab, pembrolizumab, cimiprimab, dostalimumab, rivaril, toripalimab, tislelizumab, camrelizumab, sintilimab, penaprilimab, cepalimumab, slulimumab, putelizumab, fenolinumab, atezolizumab, durvalumab, avelumab, cochilimumab, sugarymab, envorimab, adebenone, socazolimumab, or tagorimab. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with nivolumab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with pembrolizumab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with cimiprimab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with dostalimumab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with rivarilimumab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with toripalimab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with tislelizumab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with camrelizumab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with sintilimab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with penaprolimab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with cepalimumab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with slulimumab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with patelimab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with nivolumab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with fenolinumab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with atezolizumab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with durvalumab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with avelumab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with cochilimab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with sugemalimab or a variant thereof.In some embodiments, this document provides a composition comprising HX044 or a variant thereof with envorimab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with adebenonemab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with socazolimumab or a variant thereof. In some embodiments, this document provides a composition comprising HX044 or a variant thereof with tagorimab or a variant thereof.
[0064] In some embodiments, the anti-PD-1 antibody is patelimab. This document provides pharmaceutical compositions comprising a therapeutically effective amount of patelimab. In some embodiments, this document provides pharmaceutical compositions comprising a therapeutically effective amount of HX044, a therapeutically effective amount of patelimab, and a pharmaceutically acceptable carrier.
[0065] The terms "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" refer to a material suitable for administration to an individual along with an active agent without causing undesirable biological effects and without interacting with any other component of the pharmaceutical composition in a harmful manner. In some embodiments, the pharmaceutical compositions disclosed herein may comprise one or more of buffer systems, preservatives, isotonic agents, chelating agents, stabilizers, and / or surfactants, as well as various combinations thereof. The use of preservatives, isotonic agents, chelating agents, stabilizers, and surfactants in pharmaceutical compositions is well known to those skilled in the art. See Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
[0066] In some embodiments, the pharmaceutical compositions provided herein comprise HX044. In some embodiments, the pharmaceutical compositions provided herein are provided in liquid form, such as an infusion solution. HX044 may be present at various concentrations. In some embodiments, the pharmaceutical compositions provided herein comprise about 0.05-100 mg / mL of HX044. In some embodiments, the pharmaceutical compositions comprise about 1-20 mg / mL of HX044. In some embodiments, the pharmaceutical compositions provided herein comprise HX044 at concentrations of about 0.5 mg / mL, about 1.0 mg / mL, about 2.0 mg / mL, about 3.0 mg / mL, about 4.0 mg / mL, about 5.0 mg / mL, about 6.0 mg / mL, about 7.0 mg / mL, about 8.0 mg / mL, about 9.0 mg / mL, about 10.0 mg / mL, about 11.0 mg / mL, about 12.0 mg / mL, about 13.0 mg / mL, about 14.0 mg / mL, about 15.0 mg / mL, about 16.0 mg / mL, about 17.0 mg / mL, about 18.0 mg / mL, about 19.0 mg / mL, about 20.0 mg / mL, about 21.0 mg / mL, about 22.0 mg / mL, about 23.0 mg / mL, about 24.0 mg / mL, or about 25.0 mg / mL. In some embodiments, the pharmaceutical composition provided herein comprises about 10.0 mg / mL of HX044.
[0067] In some embodiments, the pharmaceutical compositions provided herein comprise an anti-PD-1 or PD-L1 antibody (e.g., patelimab or pembrolizumab). In some embodiments, the pharmaceutical compositions provided herein are provided in liquid form, such as an infusion solution. The anti-PD-1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) may be present at various concentrations. In some embodiments, the pharmaceutical compositions provided herein comprise about 0.05-100 mg / mL of an anti-PD-1 or PD-L1 antibody (e.g., patelimab or pembrolizumab). In some embodiments, the pharmaceutical compositions comprise about 1-20 mg / mL of an anti-PD-1 or PD-L1 antibody (e.g., patelimab or pembrolizumab). In some embodiments, the pharmaceutical compositions provided herein comprise about 0.05 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 6 mg / mL, about 7 mg / mL, about 8 mg / mL, about 9 mg / mL, about 10 mg / mL, about 15 mg / mL, or about 20 mg / mL of an anti-PD-1 or PD-L1 antibody (e.g., putelimab or pembrolizumab). In some embodiments, the pharmaceutical compositions provided herein comprise about 10 mg / mL of an anti-PD-1 or PD-L1 antibody (e.g., putelimab or pembrolizumab).
[0068] Pharmaceutically acceptable carriers that can be used in the compositions provided herein include any and all physiologically compatible solvents, dispersion media, coatings, antimicrobial and antifungal agents, isotonic agents, absorption delay agents, etc. In some embodiments, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal, or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active ingredient (e.g., HX044, or HX044 with putelimab or pembrolizumab) may be encapsulated in a material to protect the active ingredient from acids and other natural conditions that can inactivate it.
[0069] In some embodiments, a pharmaceutical composition in a liquid form suitable for infusion is provided. In some embodiments, a single dose of the pharmaceutical composition provided herein is a liquid formulation of about 5 ml. In some embodiments, the pharmaceutical composition is infused using an infusion solvent. In some embodiments, the solvent may be sterile water, physiological saline (0.9% sodium chloride), glucose solution, or a buffer solution (e.g., phosphate-buffered saline), or any combination thereof. In some embodiments, the solvent is physiological saline (0.9% sodium chloride).
[0070] In some embodiments, the pharmaceutically acceptable compositions provided herein are provided in single-dose units. A “single-dose unit” refers to a specific amount or quantity of a pharmaceutical substance (e.g., HX044, or HX044 with patelimab or pembrolizumab) intended to be administered to an individual as a single dose. It is a pre-measured unit designed for single-use or oral administration. A single-dose unit can be a vial, ampoule, pre-filled syringe, or pre-filled syringe for injection. A single-dose unit can be in the form of a liquid solution or lyophilized powder. In some embodiments, the single-dose unit contains an amount of HX044 of about 5 mg, about 25 mg, about 50 mg, about 75 mg, or about 100 mg. In some embodiments, the single-dose unit contains about 5 mg of HX044. In some embodiments, the single-dose unit contains about 25 mg of HX044. In some embodiments, the single-dose unit contains about 50 mg of HX044. In some embodiments, the single-dose unit contains about 75 mg of HX044. In some implementations, the single-dose unit contains approximately 100 mg of HX044.
[0071] In some embodiments, the single-dose unit contains an amount of anti-PD-1 or PD-L1 antibody of approximately 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, 1000 mg, 1200 mg, 1500 mg, or 1800 mg. In some embodiments, the single-dose unit contains approximately 200 mg of anti-PD-1 or PD-L1 antibody (e.g., putelimarab or pembrolizumab). In some embodiments, the single-dose unit may contain HX044 in amounts of about 5 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 200 mg, about 400 mg, about 500 mg, about 600 mg, about 800 mg, or about 1000 mg, and an anti-PD-1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) in amounts of about 50 mg, about 100 mg, about 200 mg, about 300 mg, or about 400 mg. In some embodiments, the single-dose unit may contain about 500 mg of HX044 and about 200 mg of patelimab. Methods of treating cancer
[0072] This article provides a method for treating cancer in a subject of need, comprising administering a therapeutically effective amount of an anti-CTLA4 / CD47 bispecific antibody to the subject. In some embodiments, the bispecific antibody comprises: (i) a light chain variable domain (VL) and a heavy chain variable domain (VH) having amino acid sequences having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NOs:7 and 8, respectively, and the VL / VH specifically binding to human CTLA4; and (ii) a CD47 binding domain having an amino acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:9. In some embodiments, the bispecific antibody comprises: (i) a light chain variable domain (VL) and a heavy chain variable domain (VH) having amino acid sequences of SEQ ID NOs:7 and 8, respectively, and the VL / VH specifically binds to human CTLA4; and (ii) a CD47 binding domain having an amino acid sequence of SEQ ID NO:9.
[0073] In some embodiments, the bispecific antibody comprises: (1) a first peptide chain (C1) comprising VL, the amino acid sequence of which has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:51; (2) a second peptide chain (C2) comprising VH, the amino acid sequence of which has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:52; and (3) a third peptide chain (C3) comprising a CD47 binding domain, the amino acid sequence of which has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:53. In some embodiments, the bispecific antibody comprises: (1) a first peptide chain (C1) comprising VL having the amino acid sequence of SEQ ID NO:51; (2) a second peptide chain (C2) comprising VH having the amino acid sequence of SEQ ID NO:52; and (3) a third peptide chain (C3) comprising a CD47 binding domain, namely HX044, having the amino acid sequence of SEQ ID NO:53.
[0074] In some embodiments, the bispecific antibody is a monoclonal antibody. In some embodiments, the bispecific antibody is isolated. In some embodiments, the bispecific antibody is substantially pure. Methods for preparing bispecific antibodies are well known in the art.
[0075] This disclosure further covers variants and equivalents of the bispecific antibodies provided herein that have at least one of the following characteristics: (i) having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% amino acid sequence identity; (ii) having the same CDRs; and (iii) containing only conserved amino acid substitutions that do not interfere with biological activity and / or non-conserved amino acid substitutions that do not interfere with biological activity. For example, variants and equivalents of HX044 have at least one of the following characteristics: (i) having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NOs:51, 52, and 53, respectively; (ii) having the same CDRs as SEQ ID NOs:51 and 52; and (iii) containing only conserved amino acid substitutions that do not interfere with biological activity and / or non-conserved amino acid substitutions that do not interfere with biological activity.
[0076] In some embodiments of the methods for treating cancer provided herein, the bispecific antibody disclosed herein (e.g., HX044) is administered at a dose not exceeding about 25.0 mg / kg. In some embodiments, the bispecific antibody is administered at a dose from about 0.1 mg / kg to about 25.0 mg / kg. In some embodiments, the bispecific antibody is administered at doses of about 0.1 mg / kg to about 8.0 mg / kg, about 1.0 mg / kg to about 8.0 mg / kg, about 1.0 mg / kg to about 15.0 mg / kg, about 1.0 mg / kg to about 25.0 mg / kg, about 2.0 mg / kg to about 8.0 mg / kg, about 2.0 mg / kg to about 15.0 mg / kg, about 2.0 mg / kg to about 25.0 mg / kg, about 4.0 mg / kg to about 8.0 mg / kg, about 4.0 mg / kg to about 15.0 mg / kg, about 4.0 mg / kg to about 25.0 mg / kg, about 8.0 mg / kg to about 15.0 mg / kg, about 8.0 mg / kg to about 25.0 mg / kg, or about 15 mg / kg to about 25.0 mg / kg. In some embodiments, the bispecific antibody (e.g., HX044) is administered at a dose of about 1.0 mg / kg to about 8.0 mg / kg. The bispecific antibody may be administered at a dose of about 1.0 mg / kg to about 15.0 mg / kg. The bispecific antibody may be administered at a dose of about 1.0 mg / kg to about 25.0 mg / kg. The bispecific antibody may be administered at a dose of about 2.0 mg / kg to about 8.0 mg / kg. The bispecific antibody may be administered at a dose of about 2.0 mg / kg to about 15.0 mg / kg. The bispecific antibody may be administered at a dose of about 2.0 mg / kg to about 25.0 mg / kg. The bispecific antibody may be administered at a dose of about 4.0 mg / kg to about 8.0 mg / kg. The bispecific antibody may be administered at a dose of about 4.0 mg / kg to about 15.0 mg / kg. The bispecific antibody may be administered at a dose of about 4.0 mg / kg to about 25.0 mg / kg. The bispecific antibody can be administered at a dose of about 8.0 mg / kg to about 15.0 mg / kg. The bispecific antibody can be administered at a dose of about 8.0 mg / kg to about 25.0 mg / kg. The bispecific antibody can be administered at a dose of about 15.0 mg / kg to about 25.0 mg / kg.
[0077] In some embodiments, the bispecific antibody (e.g., HX044) is administered at a dose selected from the group consisting of about 0.1 mg / kg, about 0.5 mg / kg, about 1.0 mg / kg, about 2.0 mg / kg, about 4.0 mg / kg, about 8.0 mg / kg, about 10.0 mg / kg, about 12.0 mg / kg, about 15.0 mg / kg, about 18.0 mg / kg, about 20.0 mg / kg, and about 25 mg / kg. In some embodiments, the bispecific antibody is administered at about 0.1 mg / kg. In some embodiments, the bispecific antibody is administered at about 0.5 mg / kg. In some embodiments, the bispecific antibody is administered at about 1.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 2.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 3.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 4.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 5.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 6.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 7.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 8.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 9.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 10.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 11.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 12.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 13.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 14.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 15.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 16.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 17.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 18.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 19.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 20.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 21.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 22.0 mg / kg. In some embodiments, the bispecific antibody is administered at about 23.0 mg / kg.In some embodiments, the bispecific antibody is administered at approximately 24.0 mg / kg. In some embodiments, the bispecific antibody is administered at approximately 25.0 mg / kg.
[0078] In some embodiments of the methods for treating cancer provided herein, the bispecific antibody disclosed herein (e.g., HX044) is administered to the subject in more than one dose. In some embodiments, the bispecific antibody is administered at dosing intervals. In some embodiments, the dosing interval remains constant during treatment with the methods provided herein. In some embodiments, the dosing interval is approximately once every 3 weeks (21 ± 3 days). In some embodiments, the dosing interval is approximately once every 18 days. In some embodiments, the dosing interval is approximately once every 19 days. In some embodiments, the dosing interval is approximately once every 20 days. In some embodiments, the dosing interval is approximately once every 21 days. In some embodiments, the dosing interval is approximately once every 22 days. In some embodiments, the dosing interval is approximately once every 23 days. In some embodiments, the dosing interval is approximately once every 24 days.
[0079] In some embodiments, more than one dose of the anti-CTLA4 / CD47 bispecific antibody (e.g., HX044) disclosed herein is administered to the subject. In some embodiments, at least 4, 8, 12, 16, 20, 24, 28, or 32 doses of the bispecific antibody are administered during treatment. In some embodiments, at least 4 doses of the bispecific antibody are administered during treatment. In some embodiments, at least 8 doses of the bispecific antibody are administered during treatment. In some embodiments, at least 12 doses of the bispecific antibody are administered during treatment. In some embodiments, at least 16 doses of the bispecific antibody are administered during treatment. In some embodiments, at least 20 doses of the bispecific antibody are administered during treatment. In some embodiments, at least 24 doses of the bispecific antibody are administered during treatment. In some embodiments, at least 28 doses of the bispecific antibody are administered during treatment. In some embodiments, at least 32 doses of the bispecific antibody are administered during treatment. In some embodiments, doses 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 of the bispecific antibody are administered to the subject during treatment. In some embodiments, one dose is administered. In some embodiments, two doses are administered. In some embodiments, three doses are administered. In some embodiments, four doses are administered. In some embodiments, five doses are administered. In some embodiments, six doses are administered. In some embodiments, seven doses are administered. In some embodiments, eight doses are administered. In some embodiments, nine doses are administered. In some embodiments, ten doses are administered. In some embodiments, eleven doses are administered. In some embodiments, twelve doses are administered. In some embodiments, thirteen doses are administered. In some embodiments, dose 14 is administered. In some embodiments, dose 15 is administered. In some embodiments, dose 16 is administered. In some embodiments, dose 17 is administered. In some embodiments, dose 18 is administered. In some embodiments, dose 19 is administered. In some embodiments, dose 20 is administered. In some embodiments, dose 21 is administered. In some embodiments, dose 22 is administered. In some embodiments, dose 23 is administered. In some embodiments, dose 24 is administered. In some embodiments, dose 25 is administered. In some embodiments, dose 26 is administered. In some embodiments, dose 27 is administered. In some embodiments, dose 28 is administered. In some embodiments, dose 29 is administered. In some embodiments, dose 30 is administered. In some embodiments, dose 31 is administered.In some embodiments, 32 doses are administered. In some embodiments, the dose of the anti-CTLA4 / CD47 bispecific antibody is administered to the subject until disease progression.
[0080] In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered for approximately one month to approximately two years. In some embodiments, the bispecific antibody is administered for approximately three months. In some embodiments, the bispecific antibody is administered for approximately six months. In some embodiments, the bispecific antibody is administered for approximately nine months. In some embodiments, the bispecific antibody is administered for approximately 12 months. In some embodiments, the bispecific antibody is administered for approximately 15 months. In some embodiments, the bispecific antibody is administered for approximately 18 months. In some embodiments, the bispecific antibody is administered for approximately 21 months. In some embodiments, the bispecific antibody is administered for approximately 24 months.
[0081] In some embodiments, the subject is administered more than one dose (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 doses), and each dose contains the same amount of bispecific antibody. In some embodiments, the amount of each dose administered ranges from about 0.1 mg / kg to about 25.0 mg / kg. In some embodiments, the amount of each dose administered is selected from the group consisting of about 0.1 mg / kg, about 0.5 mg / kg, about 1.0 mg / kg, about 2.0 mg / kg, about 4.0 mg / kg, about 8.0 mg / kg, about 10.0 mg / kg, about 12.0 mg / kg, about 15.0 mg / kg, about 20.0 mg / kg, and about 25.0 mg / kg. In some embodiments, each dose comprises about 0.1 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 0.5 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 1.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 2.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 4.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 5.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 6.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 7.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 8.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 9.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 10.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 11.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 12.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 13.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 14.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 15.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 16.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 17.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 18.0 mg / kg of the bispecific antibody.In some embodiments, each dose comprises about 19.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 20.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 21.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 22.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 23.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 24.0 mg / kg of the bispecific antibody. In some embodiments, each dose comprises about 25.0 mg / kg of the bispecific antibody.
[0082] In some embodiments, the subject is administered more than one dose (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 doses), and the amount of bispecific antibody administered at each dose may vary. In some embodiments, the dose may vary between about 0.1 mg / kg and about 25.0 mg / kg. In some embodiments, the amount of bispecific antibody administered in a single dose during treatment may be 0.1 mg / kg, about 0.5 mg / kg, about 1.0 mg / kg, about 2.0 mg / kg, about 4.0 mg / kg, about 8.0 mg / kg, about 15.0 mg / kg, or about 25.0 mg / kg. In some embodiments, the subject is administered about 0.1 mg / kg of the bispecific antibody as an initial dose. In some embodiments, the subject is given about 0.5 mg / kg of the bispecific antibody as an initial dose. In some embodiments, the subject is given about 1.0 mg / kg of the bispecific antibody as an initial dose. In some embodiments, the subject is given about 2.0 mg / kg of the bispecific antibody as an initial dose. In some embodiments, the subject is given about 4.0 mg / kg of the bispecific antibody as an initial dose. In some embodiments, the subject is given about 8.0 mg / kg of the bispecific antibody as an initial dose. In some embodiments, the subject is given about 10.0 mg / kg of the bispecific antibody as an initial dose. In some embodiments, the subject is given about 12.0 mg / kg of the bispecific antibody as an initial dose. In some embodiments, the subject is given about 15.0 mg / kg of the bispecific antibody as an initial dose. In some embodiments, the subject is given about 20.0 mg / kg of the bispecific antibody as an initial dose. In some embodiments, the subject is given about 25.0 mg / kg of the bispecific antibody as an initial dose. In some implementations, the subject is administered approximately 8.0 mg / kg of the bispecific antibody as an initial dose. Following the initial dose, the dose may be escalated to approximately 0.5 mg / kg, 1.0 mg / kg, 2.0 mg / kg, 4.0 mg / kg, 8.0 mg / kg, 10.0 mg / kg, 12.0 mg / kg, 15.0 mg / kg, 20.0 mg / kg, or 25 mg / kg, depending on the treatment regimen and patient response. The dose escalation may be gradual to ensure optimal efficacy while minimizing potential adverse reactions.
[0083] In some embodiments of the methods for treating cancer provided herein, the bispecific antibody is HX044.
[0084] In some embodiments, the bispecific antibody provided herein (e.g., HX044) can be administered systemically. In some embodiments, the bispecific antibody provided herein (e.g., HX044) can be administered by injection. In some embodiments, the bispecific antibody provided herein (e.g., HX044) can be administered by infusion. The bispecific antibody provided herein (e.g., HX044) can be administered to a subject by any method known in the art. In some embodiments, the bispecific antibody provided herein (e.g., HX044) is administered via parenteral administration. In some embodiments, the bispecific antibody provided herein (e.g., HX044) is administered via intravenous administration.
[0085] In some embodiments, the bispecific antibody (e.g., HX044) provided herein is administered by infusion. The infusion can be performed using any method known in the art for administering antibodies or treating cancer, including standard cancer treatment infusions. In some embodiments, intravenous (IV) infusion is used. In some embodiments, continuous infusion is used. Common excipients used for antibody infusion can be used for the infusion of the bispecific antibody (e.g., HX044) disclosed herein. In some embodiments, sterile water, physiological saline (0.9% sodium chloride), glucose solution, or buffer solution (e.g., phosphate-buffered saline), or any combination thereof, can be used for the infusion of the bispecific antibody (e.g., HX044). In some embodiments, the bispecific antibody (e.g., HX044) is infused with physiological saline (0.9% sodium chloride).
[0086] Commonly known infusion parameters for antibodies (e.g., infusion rate, infusion time) can be used for the infusion of the bispecific antibody (e.g., HX044). In some embodiments, the bispecific antibody is infused over 60 to 120 minutes. In some embodiments, the bispecific antibody is infused over approximately 90 minutes. In some embodiments, the bispecific antibody is infused at a constant infusion rate. In some embodiments, the infusion rate is adjusted during infusion.
[0087] In some embodiments of the methods for treating cancer provided herein, the bispecific antibody is HX044.
[0088] In some embodiments of the methods for treating cancer provided herein, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with an anti-PD-1 or anti-PD-L1 antibody. The anti-PD-1 or anti-PD-L1 antibody can be any anti-PD-1 or anti-PD-L1 antibody known in the art. In some embodiments, the anti-PD-1 or PD-L1 antibody can be nivolumab, pembrolizumab, simipremab, dostalimumab, riverimab, toripalimab, tislelizumab, camrelizumab, sintilimab, penaprilimab, cepalimumab, slulimab, putelizumab, fenolinumab, atezolizumab, durvalumab, avelumab, cochilimumab, sugmalimab, envorimab, adebenone, socazolimumab, or tagorimab. The sequence and structural characteristics of these anti-PD-1 or anti-PD-L1 antibodies are known in the art; some of them can be found in Table 4 below.
[0089] Table 4: Amino acid sequences of exemplary anti-PD-1 or anti-PD-L1 antibodies
[0090] In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with nivolumab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with pembrolizumab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with cimiprilmab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with dostalimumab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with rivanol. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with toripalimab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with tislelizumab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with camrelizumab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with sintilimab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with penaplimab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with cepallimab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with slulimab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with putelimab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with fenolinumab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with atezolizumab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with durvalumab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with avelumab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with cochilimab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with sugemalimab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with envorimab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with adebenonemab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with socalzolizumab. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is administered in combination with tagorimab.
[0091] In some embodiments, the anti-PD-1 or anti-PD-L1 antibody is administered at a dose of about 100 mg to about 1800 mg. In some embodiments, the anti-PD-1 or PD-L1 antibody is administered at a dose of about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 800 mg, about 1000 mg, about 1200 mg, about 1500 mg, or about 1800 mg. In some embodiments, the anti-PD-1 or PD-L1 antibody is administered at a dose of about 200 mg. In some embodiments, the anti-PD-1 or PD-L1 antibody is administered at a dose of about 300 mg. In some embodiments, the anti-PD-1 or PD-L1 antibody is administered at a dose of about 400 mg. In some embodiments, the anti-PD-1 or PD-L1 antibody is administered at a dose of about 500 mg. In some embodiments, the anti-PD-1 or PD-L1 antibody is administered at a dose of about 600 mg. In some embodiments, the anti-PD1 or PD-L1 antibody is administered at a dose of about 800 mg. In some embodiments, the anti-PD1 or PD-L1 antibody is administered at a dose of about 1000 mg. In some embodiments, the anti-PD1 or PD-L1 antibody is administered at a dose of about 1200 mg. In some embodiments, the anti-PD1 or PD-L1 antibody is administered at a dose of about 1500 mg. In some embodiments, the anti-PD1 or PD-L1 antibody is administered at a dose of about 1800 mg. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is co-administered with pectinumab, wherein pectinumab is administered at a dose of about 200 mg. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) is co-administered with pembrolizumab, wherein pembrolizumab is administered at a dose of about 200 mg.
[0092] In some embodiments of the methods for treating cancer provided herein, a subject is given more than one dose of an anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab). In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered at dosing intervals. In some embodiments, the dosing intervals remain fixed during treatment with the methods provided herein. In some embodiments, the dosing interval is approximately once every 3 weeks (21 ± 3 days). In some embodiments, the dosing interval is approximately once every 18 days. In some embodiments, the dosing interval is approximately once every 19 days. In some embodiments, the dosing interval is approximately once every 20 days. In some embodiments, the dosing interval is approximately once every 21 days. In some embodiments, the dosing interval is approximately once every 22 days. In some embodiments, the dosing interval is approximately once every 23 days. In some embodiments, the dosing interval is approximately once every 24 days.
[0093] In some embodiments, the subject is given more than one dose of the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab). In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered at least 4, 8, 12, 16, 20, 24, 28, or 32 times during treatment. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered at least 4 times during treatment. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered at least 8 times during treatment. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered at least 12 times during treatment. In some embodiments, at least 16 doses of the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) are administered during treatment. In some embodiments, at least 20 doses of the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) are administered during treatment. In some embodiments, at least 24 doses of the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) are administered during treatment. In some embodiments, at least 28 doses of the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) are administered during treatment. In some embodiments, at least 32 doses of the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) are administered during treatment. In some embodiments, the subject is given 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 doses of the described anti-PD1 or PD-L1 antibody (e.g., putelimarab or pembrolizumab) during treatment. In some embodiments, a single dose is given. In some embodiments, two doses are given. In some embodiments, three doses are given. In some embodiments, four doses are given. In some embodiments, five doses are given. In some embodiments, six doses are given. In some embodiments, seven doses are given. In some embodiments, eight doses are given. In some embodiments, nine doses are given. In some embodiments, ten doses are given. In some embodiments, eleven doses are given. In some embodiments, twelve doses are given. In some implementations, 13 doses are administered. In some implementations, 14 doses are administered. In some implementations, 15 doses are administered.In some embodiments, 16 doses are administered. In some embodiments, 17 doses are administered. In some embodiments, 18 doses are administered. In some embodiments, 19 doses are administered. In some embodiments, 20 doses are administered. In some embodiments, 21 doses are administered. In some embodiments, 22 doses are administered. In some embodiments, 23 doses are administered. In some embodiments, 24 doses are administered. In some embodiments, 25 doses are administered. In some embodiments, 26 doses are administered. In some embodiments, 27 doses are administered. In some embodiments, 28 doses are administered. In some embodiments, 29 doses are administered. In some embodiments, 30 doses are administered. In some embodiments, 31 doses are administered. In some embodiments, 32 doses are administered. In some embodiments, the subject is given a dose of the anti-PD1 or PD-L1 antibody (e.g., putelizumab or pembrolizumab) until disease progression.
[0094] In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered for about one month to about two years. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered for about three months. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered for about six months. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered for about nine months. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered for about 12 months. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered for about 15 months. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered for approximately 18 months. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered for approximately 21 months. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered for approximately 24 months.
[0095] In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) may be administered systemically. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) may be administered by injection. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) may be administered by infusion. The anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) may be given to the subject by any method known in the art. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered via parenteral administration. In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered via intravenous administration.
[0096] In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is administered by infusion. The infusion can be performed using any method known in the art for antibody administration or cancer treatment, including standard cancer treatment infusions. In some embodiments, intravenous (IV) infusion is used. In some embodiments, continuous infusion is used. Common excipients used for antibody infusion can be used for the infusion of the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab). In some embodiments, sterile water, physiological saline (0.9% sodium chloride), glucose solution, or buffer solution (e.g., phosphate-buffered saline), or any combination thereof, can be used for the infusion of the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab). In some embodiments, the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) is infused with physiological saline (0.9% sodium chloride).
[0097] In some embodiments, the methods provided herein include administering to a subject in need a therapeutically effective amount of the bispecific antibody disclosed herein (e.g., HX044) and a therapeutically effective amount of an anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab). The administration of treatment may be simultaneous or sequential. In some embodiments, the treatment is administered sequentially, for example, HX044 and the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) are administered sequentially. In some embodiments, the treatment is administered simultaneously, for example, HX044 and the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) are administered simultaneously. In some embodiments, the bispecific antibody disclosed herein (e.g., HX044) and the anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab) may be administered as a single composition (e.g., a liquid formulation).
[0098] This document provides a method for treating cancer in subjects of need, comprising administering to the subject a therapeutically effective amount of an anti-CTLA4 / CD47 bispecific antibody (e.g., HX044), and optionally in combination with a therapeutically effective amount of an anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab). In some embodiments, the cancer treated by the methods disclosed herein is a solid tumor. In some embodiments, the solid tumor is a head and neck cancer, such as oral cancer, nasopharyngeal carcinoma; malignant tumors of the nasal cavity and sinuses; salivary gland tumors; thyroid cancer; parathyroid cancer; tracheal tumors; or olfactory neuroblastoma. In some embodiments, the solid tumor is a central nervous system or ocular tumor, such as diffuse glioma; focal glioma; ependymoma; medulloblastoma and other embryonal tumors; atypical teratoid / rhabdoid tumors; primary central nervous system sarcoma; or ocular tumors. In some embodiments, the solid tumor is a thoracic malignancy, such as non-small cell lung cancer (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, sarcomatoid carcinoma, adenosquamous carcinoma and its variants); small cell lung cancer (including mixed histology); lung adenocarcinoma, bronchial carcinoid (typical / atypical) and large cell neuroendocrine carcinoma of the lung; thymic epithelial tumor; or malignant mesothelioma. In some embodiments, the solid tumor is a gastrointestinal or hepatobiliary cancer; gastric cancer; small intestinal adenocarcinoma; ampullary and periampullary cancer; colorectal adenocarcinoma; colon cancer, bile duct cancer, appendiceal tumor; anal canal cancer; hepatocellular carcinoma and fibrolamellar carcinoma; bile duct cancer and gallbladder cancer; pancreatic malignancy; gastrointestinal neuroendocrine tumor; or gastrointestinal stromal tumor. In some embodiments, the solid tumor is a gynecological cancer, such as ovarian cancer, fallopian tube cancer or primary peritoneal cancer; ovarian sex cord-stromal tumor; ovarian / fallopian tube / peritoneal germ cell tumor; endometrial cancer; uterine sarcoma; cervical cancer; vaginal cancer; or vulvar cancer. In some embodiments, the solid tumor is a cancer of the genitourinary or male reproductive system, such as renal cell carcinoma; urothelial carcinoma of the bladder, ureter, or renal pelvis; urachal carcinoma; prostate adenocarcinoma; testicular germ cell tumor; or adrenocortical carcinoma. In some embodiments, the solid tumor is breast cancer, such as invasive ductal carcinoma or a specific histological subtype. In some embodiments, the solid tumor is a malignant tumor of the skin or skin appendages, such as cutaneous melanoma or mucosal melanoma; non-melanoma skin cancer, including basal cell carcinoma, squamous cell carcinoma, and Merkel cell carcinoma; skin appendage cancer; Kaposi's sarcoma; cutaneous angiosarcoma; or dermatofibrosarcoma protuberans. In some embodiments, the solid tumor is a sarcoma, such as soft tissue sarcoma or osteosarcoma (osteosarcoma, chondrosarcoma, Ewing's sarcoma / primitive neuroectodermal tumor, adamantoid tumor, malignant giant cell tumor of bone, chordoma). In some embodiments, the solid tumor is an endocrine or extra-central nervous system neuroendocrine tumor, such as a pheochromocytoma or paraganglioma; a pancreatic neuroendocrine tumor; or a high-grade extrapulmonary neuroendocrine carcinoma in any location.In some embodiments, the solid tumor is a pediatric or developmental tumor, such as neuroblastoma or ganglioneuroma; Wilms' tumor and other pediatric renal tumors; hepatoblastoma; pleuroblastoma; pancreatoblastoma; extragonadal germ cell tumors; or the pediatric sarcomas and embryonal tumors described herein. In some embodiments, the solid tumor is a gestational trophoblastic tumor.
[0099] In some implementations, the cancer to be treated is advanced or metastatic cancer. As understood herein and in accordance with the art, "advanced cancer" refers to cancer that has grown significantly or spread beyond the primary tumor site but may still be confined to adjacent tissues; "metastatic cancer" means cancer that has spread to distant organs or body sites. In some implementations, the cancer to be treated is recurrent, drug-resistant, or refractory. As understood herein and in accordance with the art, "recurrent cancer" refers to the recurrence of malignancy after a period of remission or successful initial treatment. This can occur at local or distant metastases of the primary tumor site, indicating that residual cancer cells are able to survive and eventually reproliferate after treatment. As understood herein and in accordance with the art, "drug-resistant or refractory cancer" refers to cancer that does not respond to therapeutic interventions. Specifically, "drug-resistant cancer" refers to cancer that initially responded to a particular treatment but eventually developed resistance, resulting in decreased efficacy over time; while "refractory cancer" refers to cancer that is unresponsive from the start of treatment and shows no measurable improvement after treatment.
[0100] This article provides a method for treating cancer in a subject of need, comprising administering to the subject a therapeutically effective amount of an anti-CTLA4 / CD47 bispecific antibody (e.g., HX044), and optionally in combination with a therapeutically effective amount of an anti-PD1 or PD-L1 antibody (e.g., patelimab or pembrolizumab). In some embodiments, the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, cholangiocarcinoma, melanoma, or colorectal cancer. In some embodiments, the cancer to be treated is non-small cell lung cancer (NSCLC). In some embodiments, the cancer is locally advanced or metastatic NSCLC.
[0101] In some embodiments, the cancer treated by the methods disclosed herein is refractory to anti-PD-1 and / or anti-PD-L1 therapy. Cancer that is “resistant or refractory” to anti-PD-1 and / or anti-PD-L1 therapy refers to cancer that does not respond to immune checkpoint inhibitors targeting the PD-1 (programmed cell death protein 1) or PD-L1 (programmed death ligand 1) pathway. In some embodiments, the cancer is resistant to anti-PD-1 therapy. In some embodiments, the cancer is refractory to anti-PD-1 therapy. In some embodiments, the cancer is resistant to anti-PD-L1 therapy. In some embodiments, the cancer is refractory to anti-PD-L1 therapy. In some embodiments, the cancer progresses during anti-PD-1 / PD-L1 therapy. In some embodiments, the cancer progresses during anti-PD-1 therapy. In some embodiments, the cancer progresses during anti-PD-L1 therapy. In some embodiments, the cancer progresses after completion of anti-PD-1 / PD-L1 therapy. In some embodiments, the cancer progresses after anti-PD-1 therapy. In some embodiments, the cancer progresses after anti-PD-L1 treatment. Therefore, this document provides a method for treating cancer in a subject in need, comprising administering to the subject a therapeutically effective amount of an anti-CTLA4 / CD47 bispecific antibody (e.g., HX044), wherein the cancer is resistant or refractory to anti-PD-1 and / or anti-PD-L1 treatment.
[0102] This article provides a method for treating cancer in a subject of need, comprising administering to the subject a therapeutically effective amount of an anti-CTLA4 / CD47 bispecific antibody (e.g., HX044). In some embodiments, the cancer is a hot tumor. In some embodiments, the cancer is a cold tumor.
[0103] In this article, and in accordance with the understanding in the art, "hot tumors" and "cold tumors" refer to different tumor microenvironments (TMEs) that influence the effectiveness of the immune system in recognizing and attacking cancer cells. "Hot tumors" are also known as "immunologically active" or "inflammatory" tumors. These tumors are characterized by significant infiltration of immune cells within the TME, particularly cytotoxic T cells (CD8+ T cells). This immune infiltration indicates that the immune system has recognized the tumor as a threat and is attempting to initiate a response. Hot tumors typically exhibit a higher number of somatic mutations that produce neoantigens that are recognized by T cells. They tend to express immune checkpoint molecules such as PD-L1, thereby evading immune clearance by suppressing T cell activity. Hot tumors are often associated with pro-inflammatory cytokines such as interferon-γ (IFN-γ), which help recruit immune cells to the tumor site. Hot tumors generally respond well to immune checkpoint inhibitors, such as anti-PD-1 / PD-L1 or anti-CTLA-4 therapy, because the immune system has been pre-excited to attack but is regulated by inhibitory signals.
[0104] On the other hand, "cold tumors," also known as "immunologically inactive" or "non-inflammatory" tumors, lack significant immune cell infiltration. The absence of T cells or other immune components in the TME indicates that the immune system either fails to recognize the tumor or has been effectively rejected or suppressed by tumor mechanisms. Cold tumors typically have fewer mutations, meaning fewer new antigens are available to trigger an immune response. These tumors may actively reject immune cells into the TME (immune rejection) or exhibit a complete lack of immune activity (immune desert). Cold tumors often have low or absent PD-L1 expression, meaning that immune checkpoint inhibitors are less effective because the immune system does not actively attempt to attack the tumor. Cold tumors are often surrounded by an immunosuppressive microenvironment, including the presence of myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), or other factors that inhibit T cell activation and infiltration. Cold tumors generally respond poorly to immune checkpoint inhibitors because the immune system is not effectively involved in tumorigenesis.
[0105] Preclinical studies have demonstrated enhanced efficacy and safety of the bispecific antibodies (e.g., HX044) disclosed herein using various animal models (rodents / NHP), including cold tumor models that are typically unresponsive to anti-PD-1 therapy. Therefore, the methods presented herein are effective for treating both hot and cold tumors. In some embodiments, the methods presented herein can be used to treat hot tumors. In some embodiments, the methods presented herein can be used to treat cold tumors.
[0106] In some embodiments of the methods for treating cancer provided herein, the subject is a human. In some embodiments, the subject is an adult. In some embodiments, the subject has previously received anti-PD-1 / PD-L1 therapy. In some embodiments, the subject has previously received anti-PD-1 therapy. In some embodiments, the subject has previously received anti-PD-L1 therapy. In some embodiments, the subject experienced disease progression during previous anti-PD-1 / PD-L1 therapy. In some embodiments, the subject experienced disease progression during previous anti-PD-1 therapy. In some embodiments, the subject experienced disease progression during previous anti-PD-L1 therapy. In some embodiments, the subject experienced disease progression after previous anti-PD-1 / PD-L1 therapy. In some embodiments, the subject experienced disease progression after previous anti-PD-1 therapy. In some embodiments, the subject experienced disease progression after previous anti-PD-L1 therapy.
[0107] In some embodiments of the methods for treating cancer provided herein, the subject has adequate organ function (e.g., hematological function, liver function, kidney function, or coagulation function). In some embodiments, the subject has laboratory values for the following hematological functions: (i) hemoglobin ≥ 90 g / L; (ii) absolute neutrophil count ≥ 1.5 × 10⁻⁶. 9 / L; (iii) Platelet count ≥100*10 9 / L. In some implementations, subjects have the following laboratory values for liver function: (i) serum total bilirubin ≤1.5 * upper limit of normal (ULN); or for patients with total bilirubin levels >1.5 * ULN, direct bilirubin ≤ULN; (ii) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 *ULN (for subjects with liver metastases, ALT and AST ≤5 * ULN). In some implementations, subjects have the following laboratory values for kidney function: serum creatinine ≤1.5 * ULN. In some implementations, subjects have the following laboratory values for coagulation function: prothrombin time / international normalized ratio ≤1.5 * ULN or activated partial thromboplastin time ≤1.5 * ULN (for subjects using anticoagulants, prothrombin time or activated partial thromboplastin time must be within the normal range for the anticoagulant).
[0108] In some embodiments, this document provides a method for treating cancer in a subject of need, comprising administering HX044 to the subject at a dosing interval of about 0.1 mg / kg to about 25.0 mg / kg. In some embodiments, the method provided herein comprises administering to the subject 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 doses of the pharmaceutical composition. In some embodiments, HX044 is administered for about one month to about two years. In some embodiments, HX044 is administered for about three months, about six months, about nine months, about twelve months, about fifteen months, about eighteen months, about twenty-one months, or about twenty-four months. In some embodiments, HX044 is administered in combination with patelimab. In some embodiments, HX044 and patelimab are administered simultaneously. In some embodiments, each administration comprises administering about 0.1 mg / kg to about 25.0 mg / kg of HX044 and about 200 mg of patelimab. In some embodiments, a dose of HX044 (and optionally in combination with patelimab or pembrolizumab) is administered to the subject until disease progression. In some embodiments, this document provides a method for treating cancer in subjects of need comprising administering at least four doses of about 0.1 mg / kg to about 25.0 mg / kg of HX044, optionally in combination with 200 mg of patelimab, to the subject at dosing intervals of about once every 3 weeks (21 ± 3 days). In some embodiments, this document provides a method for treating cancer in a subject of need, comprising administering to the subject at a dosing interval of approximately 3 weeks (21 ± 3 days) at least 8 doses of HX044 at a dosing interval of approximately 0.1 mg / kg to approximately 25.0 mg / kg, optionally in combination with 200 mg patelimab. In some embodiments, this document provides a method for treating cancer in a subject of need, comprising administering to the subject at a dosing interval of approximately 3 weeks (21 ± 3 days) at least 12 doses of HX044 at a dosing interval of approximately 0.1 mg / kg to approximately 25.0 mg / kg, optionally in combination with 200 mg patelimab. In some embodiments, this document provides a method for treating cancer in a subject of need, comprising administering to the subject at a dosing interval of approximately 3 weeks (21 ± 3 days) at least 24 doses of HX044 at a dosing interval of approximately 0.1 mg / kg to approximately 25.0 mg / kg, optionally in combination with 200 mg patelimab.In some embodiments, this document provides a method for treating cancer in a subject of need, comprising administering to the subject at a dosing interval of approximately 32 doses of HX044 at a dose of approximately 0.1 mg / kg to approximately 25.0 mg / kg, optionally in combination with 200 mg of putelimab. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, bile duct cancer, melanoma, or colorectal cancer. In some embodiments, the cancer is non-small cell lung cancer; optionally, the cancer is locally advanced or metastatic. In some embodiments, the cancer is a hot tumor. In some embodiments, the cancer is a cold tumor. In some embodiments, the cancer is advanced or metastatic. In some embodiments, the cancer is relapsed or refractory. In some embodiments, the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy. In some embodiments, the subject is a human. In some embodiments, the subject is an adult.
[0109] In some embodiments, this document provides a method for treating cancer in a subject of need, comprising administering to the subject HX044 at dosing intervals of approximately every 3 weeks (21 ± 3 days) in doses of approximately 0.1 mg / kg, approximately 0.5 mg / kg, approximately 1.0 mg / kg, approximately 2.0 mg / kg, approximately 4.0 mg / kg, approximately 8.0 mg / kg, approximately 10.0 mg / kg, approximately 12.0 mg / kg, approximately 15.0 mg / kg, approximately 20.0 mg / kg, or approximately 25.0 mg / kg. In some embodiments, the method provided herein comprises administering to the subject 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 doses of the pharmaceutical composition. In some embodiments, HX044 is administered for approximately one month to approximately two years. In some embodiments, HX044 is administered for approximately three months, approximately six months, approximately nine months, approximately twelve months, approximately fifteen months, approximately eighteen months, approximately twenty-one months, or approximately twenty-four months. In some embodiments, HX044 is administered in combination with patelimab. In some embodiments, HX044 and patelimab are administered simultaneously. In some embodiments, each administration comprises approximately 0.1 mg / kg, approximately 0.5 mg / kg, approximately 1.0 mg / kg, approximately 2.0 mg / kg, approximately 4.0 mg / kg, approximately 8.0 mg / kg, approximately 10.0 mg / kg, approximately 12.0 mg / kg, approximately 15.0 mg / kg, approximately 20.0 mg / kg, or approximately 25.0 mg / kg of HX044 and approximately 200 mg of patelimab. In some embodiments, a dose of HX044 (and optionally in combination with patelimab or pembrolizumab) is administered to the subject until disease progression. In some embodiments, this document provides a method for treating cancer in subjects of need, comprising administering to the subject at dosing intervals of approximately every 3 weeks (21 ± 3 days) at at least four doses of HX044 at doses of approximately 0.1 mg / kg, approximately 0.5 mg / kg, approximately 1.0 mg / kg, approximately 2.0 mg / kg, approximately 4.0 mg / kg, approximately 8.0 mg / kg, approximately 10.0 mg / kg, approximately 12.0 mg / kg, approximately 15.0 mg / kg, approximately 20.0 mg / kg, or approximately 25.0 mg / kg, optionally in combination with 200 mg patelimab.In some implementations, this document provides a method for treating cancer in subjects of need, comprising administering to the subject at dosing intervals of approximately every 3 weeks (21 ± 3 days) at at least 8 doses of HX044 at doses of approximately 0.1 mg / kg, approximately 0.5 mg / kg, approximately 1.0 mg / kg, approximately 2.0 mg / kg, approximately 4.0 mg / kg, approximately 8.0 mg / kg, approximately 10.0 mg / kg, approximately 12.0 mg / kg, approximately 15.0 mg / kg, approximately 20.0 mg / kg, or approximately 25.0 mg / kg, optionally in combination with 200 mg of putelimab. In some implementations, this document provides a method for treating cancer in subjects of need, comprising administering to the subject at dosing intervals of approximately every 3 weeks (21 ± 3 days) at at least 12 doses of HX044 at doses of approximately 0.1 mg / kg, approximately 0.5 mg / kg, approximately 1.0 mg / kg, approximately 2.0 mg / kg, approximately 4.0 mg / kg, approximately 8.0 mg / kg, approximately 10.0 mg / kg, approximately 12.0 mg / kg, approximately 15.0 mg / kg, approximately 20.0 mg / kg, or approximately 25.0 mg / kg, optionally in combination with 200 mg of putelimab. In some implementations, this document provides a method for treating cancer in subjects of need, comprising administering to the subject at dosing intervals of approximately every 3 weeks (21 ± 3 days) at at least 24 doses of HX044 at doses of approximately 0.1 mg / kg, approximately 0.5 mg / kg, approximately 1.0 mg / kg, approximately 2.0 mg / kg, approximately 4.0 mg / kg, approximately 8.0 mg / kg, approximately 10.0 mg / kg, approximately 12.0 mg / kg, approximately 15.0 mg / kg, approximately 20.0 mg / kg, or approximately 25.0 mg / kg, optionally in combination with 200 mg of putelimab. In some embodiments, this document provides a method for treating cancer in subjects of need, comprising administering to the subject at dosing intervals of approximately every 3 weeks (21 ± 3 days) at at least 32 doses of HX044 at doses of approximately 0.1 mg / kg, approximately 0.5 mg / kg, approximately 1.0 mg / kg, approximately 2.0 mg / kg, approximately 4.0 mg / kg, approximately 8.0 mg / kg, approximately 10.0 mg / kg, approximately 12.0 mg / kg, approximately 15.0 mg / kg, approximately 20.0 mg / kg, or approximately 25.0 mg / kg, optionally in combination with 200 mg of putelimab. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, bile duct carcinoma, melanoma, or colorectal cancer. In some embodiments, the cancer is non-small cell lung cancer; optionally, the cancer is locally advanced or metastatic. In some embodiments, the cancer is a thermal tumor.In some embodiments, the cancer is a cold tumor. In some embodiments, the cancer is advanced or metastatic. In some embodiments, the cancer is recurrent or refractory. In some embodiments, the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy. In some embodiments, the subject is a human. In some embodiments, the subject is an adult.
[0110] In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering approximately 2.0 mg / kg of HX044 to the subject at a dosing interval of approximately once every 3 weeks (21 ± 3 days). In some embodiments, the method provided herein comprises administering to the subject 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 doses of the pharmaceutical composition. In some embodiments, HX044 is administered for approximately one month to approximately 2 years. In some embodiments, HX044 is administered for approximately 3 months, approximately 6 months, approximately 9 months, approximately 12 months, approximately 15 months, approximately 18 months, approximately 21 months, or approximately 24 months. In some embodiments, HX044 is administered in combination with patelimab. In some embodiments, HX044 is administered concurrently with patelimab. In some embodiments, each administration comprises administering approximately 2.0 mg / kg of HX044 and approximately 200 mg of patelimab. In some embodiments, a dose of HX044 (and optionally in combination with patelimab or pembrolizumab) is administered to the subject until disease progression. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering at least four doses of approximately 2.0 mg / kg of HX044, optionally in combination with 200 mg of patelimab, to the subject at a dosing interval of approximately every 3 weeks (21 ± 3 days). In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering at least eight doses of approximately 2.0 mg / kg of HX044, optionally in combination with 200 mg of patelimab, to the subject at a dosing interval of approximately every 3 weeks (21 ± 3 days). In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 12 doses of HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg patelimab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 24 doses of HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg patelimab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 32 doses of HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg patelimab. In some embodiments, the cancer is a solid tumor.In some embodiments, the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, bile duct cancer, melanoma, or colorectal cancer. In some embodiments, the cancer is non-small cell lung cancer; optionally, the cancer is locally advanced or metastatic. In some embodiments, the cancer is a hot tumor. In some embodiments, the cancer is a cold tumor. In some embodiments, the cancer is advanced or metastatic. In some embodiments, the cancer is recurrent or refractory. In some embodiments, the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy. In some embodiments, the subject is a human. In some embodiments, the subject is an adult.
[0111] In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering approximately 4.0 mg / kg of HX044 to the subject at a dosing interval of approximately once every 3 weeks (21 ± 3 days). In some embodiments, the method provided herein comprises administering to the subject 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 doses of the pharmaceutical composition. In some embodiments, HX044 is administered for approximately one month to approximately 2 years. In some embodiments, HX044 is administered for approximately 3 months, approximately 6 months, approximately 9 months, approximately 12 months, approximately 15 months, approximately 18 months, approximately 21 months, or approximately 24 months. In some embodiments, HX044 is administered in combination with patelimab. In some embodiments, HX044 is administered concurrently with patelimab. In some embodiments, each administration comprises administering approximately 4.0 mg / kg of HX044 and approximately 200 mg of patelimab. In some embodiments, a dose of HX044 (and optionally in combination with patelimab or pembrolizumab) is administered to the subject until disease progression. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering at least four doses of approximately 4.0 mg / kg of HX044, optionally in combination with 200 mg of patelimab, to the subject at a dosing interval of approximately every 3 weeks (21 ± 3 days). In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering at least eight doses of approximately 4.0 mg / kg of HX044, optionally in combination with 200 mg of patelimab, to the subject at a dosing interval of approximately every 3 weeks (21 ± 3 days). In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 12 doses of HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg patelimab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 24 doses of HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg patelimab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 32 doses of HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg patelimab. In some embodiments, the cancer is a solid tumor.In some embodiments, the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, bile duct cancer, melanoma, or colorectal cancer. In some embodiments, the cancer is non-small cell lung cancer; optionally, the cancer is locally advanced or metastatic. In some embodiments, the cancer is a hot tumor. In some embodiments, the cancer is a cold tumor. In some embodiments, the cancer is advanced or metastatic. In some embodiments, the cancer is recurrent or refractory. In some embodiments, the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy. In some embodiments, the subject is a human. In some embodiments, the subject is an adult.
[0112] In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering approximately 8.0 mg / kg of HX044 to the subject at a dosing interval of approximately once every 3 weeks (21 ± 3 days). In some embodiments, the method provided herein comprises administering to the subject 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 doses of the pharmaceutical composition. In some embodiments, HX044 is administered for approximately one month to approximately 2 years. In some embodiments, HX044 is administered for approximately 3 months, approximately 6 months, approximately 9 months, approximately 12 months, approximately 15 months, approximately 18 months, approximately 21 months, or approximately 24 months. In some embodiments, HX044 is administered in combination with patelimab. In some embodiments, HX044 is administered concurrently with patelimab. In some embodiments, each administration comprises administering approximately 8.0 mg / kg of HX044 and approximately 200 mg of patelimab. In some embodiments, a dose of HX044 (and optionally in combination with patelimab or pembrolizumab) is administered to the subject until disease progression. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering at least four doses of approximately 8.0 mg / kg of HX044, optionally in combination with 200 mg of patelimab, to the subject at a dosing interval of approximately every 3 weeks (21 ± 3 days). In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering at least eight doses of approximately 8.0 mg / kg of HX044, optionally in combination with 200 mg of patelimab, to the subject at a dosing interval of approximately every 3 weeks (21 ± 3 days). In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 12 doses of HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg patelimab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 24 doses of HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg patelimab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 32 doses of HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg patelimab. In some embodiments, the cancer is a solid tumor.In some embodiments, the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, bile duct cancer, melanoma, or colorectal cancer. In some embodiments, the cancer is non-small cell lung cancer; optionally, the cancer is locally advanced or metastatic. In some embodiments, the cancer is a hot tumor. In some embodiments, the cancer is a cold tumor. In some embodiments, the cancer is advanced or metastatic. In some embodiments, the cancer is recurrent or refractory. In some embodiments, the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy. In some embodiments, the subject is a human. In some embodiments, the subject is an adult.
[0113] In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering approximately 10.0 mg / kg of HX044 to the subject at a dosing interval of approximately once every 3 weeks (21 ± 3 days). In some embodiments, the method provided herein comprises administering the pharmaceutical composition to the subject at doses of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 times. In some embodiments, HX044 is administered for approximately one month to approximately 2 years. In some embodiments, HX044 is administered for approximately 3 months, approximately 6 months, approximately 9 months, approximately 12 months, approximately 15 months, approximately 18 months, approximately 21 months, or approximately 24 months. In some embodiments, HX044 is administered in combination with putelimab. In some embodiments, HX044 is administered concurrently with patelimab. In some embodiments, each administration comprises administering approximately 10.0 mg / kg of HX044 and approximately 200 mg of patelimab. In some embodiments, a dose of HX044 (and optionally in combination with patelimab or pembrolizumab) is administered to the subject until disease progression. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering at least four doses of approximately 10.0 mg / kg of HX044 to the subject at dosing intervals of approximately every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of patelimab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering at least eight doses of approximately 10.0 mg / kg of HX044 to the subject at dosing intervals of approximately every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of patelimab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 12 doses of about 10.0 mg / kg HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of pectinumab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 24 doses of about 10.0 mg / kg HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of pectinumab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 32 doses of about 10.0 mg / kg HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of pectinumab.In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, bile duct cancer, melanoma, or colorectal cancer. In some embodiments, the cancer is non-small cell lung cancer; optionally, the cancer is locally advanced or metastatic. In some embodiments, the cancer is a hot tumor. In some embodiments, the cancer is a cold tumor. In some embodiments, the cancer is advanced or metastatic. In some embodiments, the cancer is recurrent or refractory. In some embodiments, the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy. In some embodiments, the subject is a human. In some embodiments, the subject is an adult.
[0114] In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering approximately 15.0 mg / kg of HX044 to the subject at a dosing interval of approximately once every 3 weeks (21 ± 3 days). In some embodiments, the method provided herein comprises administering to the subject 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 doses of the pharmaceutical composition. In some embodiments, HX044 is administered for approximately one month to approximately 2 years. In some embodiments, HX044 is administered for approximately 3 months, approximately 6 months, approximately 9 months, approximately 12 months, approximately 15 months, approximately 18 months, approximately 21 months, or approximately 24 months. In some embodiments, HX044 is administered in combination with putelimab. In some embodiments, HX044 is administered concurrently with patelimab. In some embodiments, each administration comprises administering approximately 15.0 mg / kg of HX044 and approximately 200 mg of patelimab. In some embodiments, a dose of HX044 (and optionally in combination with patelimab or pembrolizumab) is administered to the subject until disease progression. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering at least four doses of approximately 15.0 mg / kg of HX044 to the subject at dosing intervals of approximately every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of patelimab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering at least eight doses of approximately 15.0 mg / kg of HX044 to the subject at dosing intervals of approximately every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of patelimab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 12 doses of about 15.0 mg / kg HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of pectinumab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 24 doses of about 15.0 mg / kg HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of pectinumab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 32 doses of about 15.0 mg / kg HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of pectinumab.In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, bile duct cancer, melanoma, or colorectal cancer. In some embodiments, the cancer is non-small cell lung cancer; optionally, the cancer is locally advanced or metastatic. In some embodiments, the cancer is a hot tumor. In some embodiments, the cancer is a cold tumor. In some embodiments, the cancer is advanced or metastatic. In some embodiments, the cancer is recurrent or refractory. In some embodiments, the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy. In some embodiments, the subject is a human. In some embodiments, the subject is an adult.
[0115] In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering approximately 20.0 mg / kg of HX044 to the subject at a dosing interval of approximately once every 3 weeks (21 ± 3 days). In some embodiments, the method provided herein comprises administering to the subject 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 doses of the pharmaceutical composition. In some embodiments, HX044 is administered for approximately one month to approximately 2 years. In some embodiments, HX044 is administered for approximately 3 months, approximately 6 months, approximately 9 months, approximately 12 months, approximately 15 months, approximately 18 months, approximately 21 months, or approximately 24 months. In some embodiments, HX044 is administered in combination with patelimab. In some embodiments, HX044 is administered concurrently with patelimab. In some embodiments, each administration comprises administering approximately 20.0 mg / kg of HX044 and approximately 200 mg of patelimab. In some embodiments, a dose of HX044 (and optionally in combination with patelimab or pembrolizumab) is administered to the subject until disease progression. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering at least four doses of approximately 20.0 mg / kg of HX044 to the subject at dosing intervals of approximately every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of patelimab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering at least eight doses of approximately 20.0 mg / kg of HX044 to the subject at dosing intervals of approximately every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of patelimab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 12 doses of about 20.0 mg / kg HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of pectinumab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 24 doses of about 20.0 mg / kg HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of pectinumab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 32 doses of about 20.0 mg / kg HX044 at a dosing interval of about once every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of pectinumab.In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, bile duct cancer, melanoma, or colorectal cancer. In some embodiments, the cancer is non-small cell lung cancer; optionally, the cancer is locally advanced or metastatic. In some embodiments, the cancer is a hot tumor. In some embodiments, the cancer is a cold tumor. In some embodiments, the cancer is advanced or metastatic. In some embodiments, the cancer is recurrent or refractory. In some embodiments, the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy. In some embodiments, the subject is a human. In some embodiments, the subject is an adult.
[0116] In some embodiments, this document provides a method for treating cancer in subjects with this need, comprising administering approximately 25.0 mg / kg of HX044 to the subject at a dosing interval of approximately once every 3 weeks (21 ± 3 days). In some embodiments, the method provided herein comprises administering to the subject 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 doses of the pharmaceutical composition. In some embodiments, HX044 is administered for approximately one month to approximately 2 years. In some embodiments, HX044 is administered for approximately 3 months, approximately 6 months, approximately 9 months, approximately 12 months, approximately 15 months, approximately 18 months, approximately 21 months, or approximately 24 months. In some embodiments, HX044 is administered in combination with patelimab. In some embodiments, HX044 is administered concurrently with patelimab. In some embodiments, each administration comprises administering approximately 25.0 mg / kg of HX044 and approximately 200 mg of patelimab. In some embodiments, a dose of HX044 (optionally in combination with patelimab or pembrolizumab) is administered to the subject until disease progression. In some embodiments, this document provides a method for treating cancer in subjects with this need, comprising administering at least four doses of approximately 25.0 mg / kg of HX044, optionally in combination with 200 mg of patelimab, to the subject at a dosing interval of approximately every 3 weeks (21 ± 3 days). In some embodiments, this document provides a method for treating cancer in subjects with this need, comprising administering at least eight doses of approximately 25.0 mg / kg of HX044, optionally in combination with 200 mg of patelimab, to the subject at a dosing interval of approximately every 3 weeks (21 ± 3 days). In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 12 doses of HX044 at a dosing interval of approximately every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of pectinumab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 24 doses of HX044 at a dosing interval of approximately every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of pectinumab. In some embodiments, this document provides a method for treating cancer in a subject with this need, comprising administering to the subject at least 32 doses of HX044 at a dosing interval of approximately every 3 weeks (21 ± 3 days), optionally in combination with 200 mg of pectinumab. In some embodiments, the cancer is a solid tumor.In some embodiments, the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, bile duct cancer, melanoma, or colorectal cancer. In some embodiments, the cancer is non-small cell lung cancer; optionally, the cancer is locally advanced or metastatic. In some embodiments, the cancer is a hot tumor. In some embodiments, the cancer is a cold tumor. In some embodiments, the cancer is advanced or metastatic. In some embodiments, the cancer is relapsed or refractory. In some embodiments, the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy. In some embodiments, the subject is a human. In some embodiments, the subject is an adult.
[0117] Compared to therapeutics that target CD47 only or immune checkpoint inhibitors with a single target (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA4), the approach presented herein achieves enhanced efficacy and improved safety. Without being bound by theory, the bispecific antibody disclosed herein (e.g., HX044) exhibits reduced affinity for human CTLA4 (300-fold lower than ipilimumab) and minimizes its “blocking function” to reduce immune-related adverse events (irAEs), a major safety hindrance for anti-CTLA4 antibodies. It also has reduced affinity for CD47 to reduce hematological toxicities, such as anemia and thrombocytopenia observed in other CD47-targeting molecules. This reduced affinity for each molecule facilitates the specific entry of the bispecific antibody disclosed herein (e.g., HX044) into Treg cells in the TME while avoiding nonspecific binding to peripheral cells, including RBCs and systemic Treg cells. Despite reduced affinity for CTLA4 or CD47 single-positive cells, the bispecific antibody is able to target Tregs with enhanced affinity due to the co-overexpression of CTLA4 and CD47 on Treg cells, resulting in efficient cis binding on Tregs.
[0118] The methods provided herein enable enhanced efficacy in cancer treatment. In some embodiments, the methods provided herein remodel the tumor microenvironment (TME) in a manner favorable to antitumor immunity. In some embodiments, the methods provided herein selectively eliminate CTLA-4 and CD47 double-positive cells relative to CD47 single-positive cells via antibody-dependent cell-mediated cytotoxicity. In some embodiments, the methods provided herein deplete tumor-infiltrating lymphocytes (TILs) – regulatory T cells (Treg cells) or Treg cells. In some embodiments, the methods provided herein enhance the T cell response against said cancer. In some embodiments, the methods provided herein enhance T cell proliferation and / or activity. The antigen-specific T cell response can be measured using any suitable antigen-specific T cell response indicator. Non-limiting examples of such suitable indicators include increased T cell proliferation and / or increased cytokine production in the presence of said antibody. In some embodiments, the production of interleukin-2 and / or interferon-γ by said antigen-specific T cells is stimulated. In some embodiments, the methods provided herein increase cytokine levels in the TME. In some embodiments, the methods provided herein increase interleukin-2 levels in the TME. In some embodiments, the methods provided herein increase interferon-γ levels in the TME. In some embodiments, the methods provided herein exhibit a low antigen sink effect. In some embodiments, the methods provided herein for treating cancer achieve greater tumor growth inhibition than standard therapy or agents targeting only CD47 or immune checkpoint inhibitors with a single target (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA-4). In some embodiments, the methods provided herein for treating cancer effectively inhibit tumor growth. In some embodiments, the methods provided herein effectively lead to tumor regression. In some embodiments, the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy. In some embodiments, the cancer is a hot tumor. In some embodiments, the cancer is a cold tumor.
[0119] The methods described herein enable improved safety in cancer treatment. The bispecific antibodies disclosed herein (e.g., HX044) selectively eliminate CTLA4 and CD47-positive cells through antibody-dependent cell-mediated cytotoxicity (ADCC). Hematologic toxicity refers to adverse effects on the blood and bone marrow, including erythrocyte, leukocyte, and / or thrombocytopenia. Because the bispecific antibodies disclosed herein (e.g., HX044) specifically target Treg cells in the TME and avoid nonspecific binding to peripheral cells, the methods described herein exhibit low hematologic toxicity in some embodiments. In some embodiments, the methods described herein for treating cancer have improved safety (e.g., lower hematologic toxicity) compared to therapeutic agents that target CD47 only (e.g., Sirpα). Immune-related adverse events (irAEs) are inflammatory toxicities that occur when immune checkpoint inhibitors—such as anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapies—disrupt immune self-tolerance and enhance T cell activity, making them target not only tumor cells but also normal tissues. These events stem from an overactivated immune response, leading to autoimmune-like effects across multiple organ systems, including the skin, gastrointestinal tract, liver, endocrine glands, lungs, and nervous system. Clinically, irAEs can range from mild to severe and can manifest as dermatitis, colitis, hepatitis, endocrine disorders, pneumonia, or neuropathy. In some embodiments, the methods provided herein have a low risk of triggering irAEs due to their reduced affinity for CTLA4+ / CD47- cells. In some embodiments, the methods provided herein have a low risk of triggering cytokine release syndrome (CRS). In some embodiments, the methods provided herein have a lower risk of triggering irAEs than single-target immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA-4). In some embodiments, the methods provided herein have a lower risk of triggering CRS than single-target immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA-4). Reagent test kit
[0120] In some embodiments, this disclosure provides a variety of kits for conveniently and / or efficiently implementing the methods of this disclosure. In some embodiments, the kits provided herein include the anti-CTLA4 / CD47 bispecific antibody (e.g., HX044) disclosed herein. In some embodiments, the kits also provided herein include a single-dose unit of the anti-CTLA4 / CD47 bispecific antibody (e.g., HX044) disclosed herein. In some embodiments, the kits provided herein also include an anti-PD-1 or PD-L1 antibody. In some embodiments, the anti-PD-1 or PD-L1 antibody may be nivolumab, pembrolizumab, simmiprimab, dostalimumab, rivaril, toripalimab, tislelizumab, camrelizumab, sintilimab, penaprilimab, cepalimab, slulimab, patelimab, fenolinumab, atezolizumab, durvalumab, avelumab, cochilimumab, sugelimumab, envorimab, adebenone, socazolimumab, or tagorimab. In some embodiments, the anti-PD-1 or PD-L1 antibody is patelimab. In some embodiments, the kits provided herein include HX044 for cancer treatment and patelimab. In some embodiments, the anti-PD-1 or PD-L1 antibody is pembrolizumab. In some embodiments, the kits provided herein include HX044 and pembrolizumab for cancer treatment. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, bile duct cancer, melanoma, or colorectal cancer. In some embodiments, the cancer is non-small cell lung cancer; optionally, the cancer is locally advanced or metastatic. In some embodiments, the cancer is a hot tumor. In some embodiments, the cancer is a cold tumor. In some embodiments, the cancer is advanced or metastatic. In some embodiments, the cancer is relapsed or refractory.
[0121] Typically, the kit will include sufficient quantity and / or number of components to allow the user to administer multiple treatments and / or conduct multiple experiments on the subject.
[0122] Any pharmaceutical composition disclosed herein may be included in a kit. In some embodiments, the kit may also include reagents and / or instructions for preparing and / or synthesizing the compounds and / or pharmaceutical compositions disclosed herein. In some embodiments, the kit may also include one or more buffer solutions.
[0123] In some embodiments, kit components may be packaged in aqueous media or lyophilized form. The kit's container device typically includes at least one vial, test tube, flask, bottle, syringe, or other container device for holding and appropriately aliquoting the components. When more than one kit component is present (labeling reagents and labels may be packaged together), the kit may also include second, third, or other additional containers for holding the additional components separately. In some embodiments, the kit may also include a second container device for containing sterile, pharmaceutically acceptable buffers and / or other diluents. In some embodiments, various component combinations may be contained in one or more vials. The kits of this disclosure may also typically include a device for containing the compounds and / or pharmaceutical compositions (e.g., proteins) of this disclosure, as well as any other reagent containers, for close packing at commercial sale. Such containers may include injection-molded or blow-molded plastic containers in which the desired vials are held.
[0124] In some embodiments, the reagent kit components are provided in the form of one and / or more liquid solutions. In some embodiments, the liquid solution is an aqueous solution, particularly a sterile aqueous solution. In some embodiments, the reagent kit components may be provided as a dry powder. When the reagents and / or components are provided in dry powder form, the powder can be reconstituted by adding an appropriate volume of solvent. In some embodiments, it is also envisioned that the solvent may also be provided in a separate container.
[0125] In some implementations, the kit may include instructions for using the kit components and instructions for using any other reagents not included in the kit. These instructions may include implementable variations. Exemplary Implementation
[0126] Implementation Scheme 1: A method for treating cancer in a subject in need, comprising administering to the subject a therapeutically effective amount of an anti-CTLA4 / CD47 bispecific antibody; wherein the bispecific antibody comprises (i) a light chain variable domain (VL) and a heavy chain variable domain (VH) having amino acid sequences that are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, respectively, identical to those of SEQ ID NOs:7 and 8, and the VL / VH specifically binds to human CTLA4; and (ii) a CD47 binding domain having an amino acid sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5%, identical to those of SEQ ID NO:9; and wherein the bispecific antibody is administered at a dose of about 0.1 mg / kg to about 25.0 mg / kg, based on the subject's weight.
[0127] Implementation Scheme 2: The method of claim 1, wherein (i) the VL and VH have amino acid sequences of SEQ ID NOs:7 and 8, respectively; and (ii) the CD47 binding domain has an amino acid sequence of SEQ ID NO:9.
[0128] Implementation Scheme 3: The method of claim 1 or 2, wherein the bispecific antibody comprises (1) a first peptide chain (C1) comprising the VL and a light chain constant region (CL); (2) a second peptide chain (C2) comprising the VH and a heavy chain constant region (CH); and (3) a third peptide chain (C3) comprising the CD47 binding domain and an Fc region.
[0129] Implementation Scheme 4: The method of claim 3, wherein (1) the amino acid sequence of C1 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO: 51; (2) the amino acid sequence of C2 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO: 52; and (3) the amino acid sequence of C3 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO: 53.
[0130] Implementation Scheme 5: The method of claim 4, wherein C1, C2 and C3 have amino acid sequences of SEQ ID NOs: 51, 52 and 53, respectively.
[0131] Implementation Scheme 6: The method of any one of claims 1 to 5, wherein the bispecific antibody is administered at a dose of about 0.1 mg / kg to about 8.0 mg / kg, about 1.0 mg / kg to about 8.0 mg / kg, about 1.0 mg / kg to about 15.0 mg / kg, about 1.0 mg / kg to about 25.0 mg / kg, about 2.0 mg / kg to about 8.0 mg / kg, about 2.0 mg / kg to about 15.0 mg / kg, about 2.0 mg / kg to about 25.0 mg / kg, about 4.0 mg / kg to about 8.0 mg / kg, about 4.0 mg / kg to about 15.0 mg / kg, about 4.0 mg / kg to about 25.0 mg / kg, about 8 mg / kg to about 15.0 mg / kg, about 8 mg / kg to about 25.0 mg / kg, or about 15 mg / kg to about 25.0 mg / kg.
[0132] Implementation Scheme 7: The method of claim 6, wherein the bispecific antibody is administered at a dose selected from the group consisting of about 0.1 mg / kg, about 0.5 mg / kg, about 1.0 mg / kg, about 2.0 mg / kg, about 4.0 mg / kg, about 8.0 mg / kg, about 10.0 mg / kg, about 12.0 mg / kg, about 15.0 mg / kg, about 20.0 mg / kg, and about 25.0 mg / kg.
[0133] Implementation Scheme 8: The method of claim 6, wherein the bispecific antibody is administered at a dose of about 2.0 mg / kg.
[0134] Implementation Scheme 9: The method of claim 6, wherein the bispecific antibody is administered at a dose of about 4.0 mg / kg.
[0135] Implementation Scheme 10: The method of claim 6, wherein the bispecific antibody is administered at a dose of about 8.0 mg / kg.
[0136] Implementation Scheme 11: The method of claim 6, wherein the bispecific antibody is administered at a dose of about 10.0 mg / kg.
[0137] Implementation Scheme 12: The method of claim 6, wherein the bispecific antibody is administered at a dose of about 12.0 mg / kg.
[0138] Implementation Scheme 13: The method of claim 6, wherein the bispecific antibody is administered at a dose of about 15.0 mg / kg.
[0139] Implementation Scheme 14: The method of claim 6, wherein the bispecific antibody is administered at a dose of about 20.0 mg / kg.
[0140] Implementation Scheme 15: The method of claim 6, wherein the bispecific antibody is administered at a dose of about 25.0 mg / kg.
[0141] Implementation Scheme 16: The method of any one of claims 1 to 15, wherein more than one dose of the bispecific antibody is administered.
[0142] Implementation Scheme 17: The method of claim 16, wherein the bispecific antibody is administered at least 4 times, at least 8 times, at least 12 times, at least 16 times, at least 20 times, at least 24 times, at least 28 times, or at least 32 times.
[0143] Implementation Scheme 18: The method of claim 16 or 17, wherein the bispecific antibody is administered at a dosing interval of approximately once every 3 weeks.
[0144] Implementation Scheme 19: The method of any one of claims 1 to 18, wherein the bispecific antibody is administered in the form of a liquid formulation.
[0145] Implementation Scheme 20: The method of any one of claims 1 to 19, wherein the bispecific antibody is administered via intravenous infusion.
[0146] Implementation Scheme 21: The method of claim 20, wherein a single dose of the bispecific antibody is administered over a period of 60 to 120 minutes.
[0147] Implementation Scheme 22: The method of claim 21, wherein a single dose of the bispecific antibody is administered within approximately 90 minutes.
[0148] Implementation Scheme 23: The method of any one of claims 1 to 22, wherein the cancer is a solid tumor.
[0149] Implementation Scheme 24: The method of claim 23, wherein the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, bile duct cancer, melanoma, or colorectal cancer.
[0150] Implementation Scheme 25: The method of claim 23, wherein the cancer is non-small cell lung cancer; optionally, wherein the cancer is locally advanced or metastatic.
[0151] Implementation Scheme 26: The method of any one of claims 1 to 25, wherein the cancer is a thermal tumor.
[0152] Implementation Scheme 27: The method of any one of claims 1 to 25, wherein the cancer is a cold tumor.
[0153] Implementation Scheme 28: The method of any one of claims 1 to 25, wherein the cancer is infiltrated by immune cells.
[0154] Implementation Scheme 29: The method of any one of claims 1 to 28, wherein the cancer is advanced or metastatic.
[0155] Implementation Scheme 30: The method of any one of claims 1 to 29, wherein the cancer is recurrent, drug-resistant, or refractory.
[0156] Implementation Scheme 31: The method of claim 30, wherein the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy.
[0157] Implementation Scheme 32: The method of any one of claims 1 to 31, wherein the subject is a human being.
[0158] Implementation Scheme 33: The method of claim 32, wherein the subject has received anti-PD-1 / PD-L1 treatment.
[0159] Implementation Scheme 34: The method of any one of claims 1 to 33, wherein the method (1) depletes tumor-infiltrating lymphocytes (TILs)-regulatory T cells (Treg cells) or Treg cells in the tumor microenvironment (TME); (2) increases cytokine levels in the TME; (3) enhances T cell proliferation and / or activity against the cancer; (4) enhances macrophage-mediated phagocytosis; (5) enhances dendritic cell-mediated antigen presentation; or any combination of (1)-(5).
[0160] Implementation Scheme 35: The method of any one of claims 1 to 33, wherein the method (1) selectively eliminates CTLA4 and CD47 positive cells by antibody-dependent cell-mediated cytotoxicity (ADCC); (2) has a low risk of triggering immune-related adverse events (irAEs); (3) has a low risk of triggering cytokine release syndrome (CRS); or (4) has reduced hematologic toxicity; or any combination of (1) to (4).
[0161] Implementation Scheme 36: The method of any one of claims 1 to 35 further includes administering a therapeutically effective amount of anti-PD1 or PD-L1 antibody.
[0162] Implementation Scheme 37: A method for treating cancer in a subject in need, comprising administering to the subject a therapeutically effective amount of an anti-CTLA4 / CD47 bispecific antibody and a therapeutically effective amount of an anti-PD1 or PD-L1 antibody.
[0163] Implementation Scheme 38: The method of claim 37, wherein the bispecific antibody comprises (i) a light chain variable domain (VL) and a heavy chain variable domain (VH), the amino acid sequences of which have at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NOs:7 and 8, respectively, and the VL / VH specifically binds to human CTLA4; and (ii) a CD47 binding domain, the amino acid sequence of which has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:9.
[0164] Implementation Scheme 39: The method of claim 37 or 38, wherein (i) the VL and VH have amino acid sequences of SEQ ID NOs:7 and 8, respectively; and (ii) the CD47 binding domain has an amino acid sequence of SEQ ID NO:9.
[0165] Implementation Scheme 40: The method of any one of claims 37 to 39, wherein the bispecific antibody comprises (1) a first peptide chain (C1) comprising the VL and a light chain constant region (CL); (2) a second peptide chain (C2) comprising the VH and a heavy chain constant region (CH); and (3) a third peptide chain (C3) comprising the CD47 binding domain and an Fc region.
[0166] Implementation Scheme 41: The method of claim 40, wherein (1) the amino acid sequence of C1 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO: 51; (2) the amino acid sequence of C2 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO: 52; and (3) the amino acid sequence of C3 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO: 53.
[0167] Implementation Scheme 42: The method of claim 41, wherein C1, C2 and C3 have amino acid sequences of SEQ ID NOs: 51, 52 and 53, respectively.
[0168] Implementation Scheme 43: The method of any one of claims 37 to 42, wherein the bispecific antibody is administered at a dose of about 0.1 mg / kg to about 25.0 mg / kg, based on the subject's weight.
[0169] Implementation Scheme 44: The method of claim 43, wherein the bispecific antibody is administered at a dose of about 0.1 mg / kg to about 8.0 mg / kg, about 1.0 mg / kg to about 8.0 mg / kg, about 1.0 mg / kg to about 15.0 mg / kg, about 1.0 mg / kg to about 25.0 mg / kg, about 2.0 mg / kg to about 8.0 mg / kg, about 2.0 mg / kg to about 15.0 mg / kg, about 2.0 mg / kg to about 25.0 mg / kg, about 4.0 mg / kg to about 8.0 mg / kg, about 4.0 mg / kg to about 15.0 mg / kg, about 4.0 mg / kg to about 25.0 mg / kg, about 8.0 mg / kg to about 15.0 mg / kg, about 8.0 mg / kg to about 25.0 mg / kg, or about 15 mg / kg to about 25.0 mg / kg.
[0170] Implementation Scheme 45: The method of claim 43, wherein the bispecific antibody is administered at a dose selected from the group consisting of about 0.1 mg / kg, about 0.5 mg / kg, about 1.0 mg / kg, about 2.0 mg / kg, about 4.0 mg / kg, about 8.0 mg / kg, about 10.0 mg / kg, about 12.0 mg / kg, about 15.0 mg / kg, about 20.0 mg / kg, and about 25.0 mg / kg.
[0171] Implementation Scheme 46: The method of claim 43, wherein the bispecific antibody is administered at a dose of about 2.0 mg / kg.
[0172] Implementation Scheme 47: The method of claim 43, wherein the bispecific antibody is administered at a dose of about 4.0 mg / kg.
[0173] Implementation Scheme 48: The method of claim 43, wherein the bispecific antibody is administered at a dose of about 8.0 mg / kg.
[0174] Implementation Scheme 49: The method of claim 43, wherein the bispecific antibody is administered at a dose of about 10.0 mg / kg.
[0175] Implementation Scheme 50: The method of claim 43, wherein the bispecific antibody is administered at a dose of about 12.0 mg / kg.
[0176] Implementation Scheme 51: The method of claim 43, wherein the bispecific antibody is administered at a dose of about 15.0 mg / kg.
[0177] Implementation Scheme 52: The method of claim 43, wherein the bispecific antibody is administered at a dose of about 20.0 mg / kg.
[0178] Implementation Scheme 53: The method of claim 43, wherein the bispecific antibody is administered at a dose of about 25.0 mg / kg.
[0179] Implementation Scheme 54: The method of any one of claims 37 to 53, wherein the bispecific antibody is administered in the form of a liquid formulation.
[0180] Implementation Scheme 55: The method of any one of claims 37 to 54, wherein the bispecific antibody is administered via intravenous infusion.
[0181] Implementation Scheme 56: The method of any one of claims 37 to 55, wherein the bispecific antibody is administered at a dosing interval of approximately once every 3 weeks.
[0182] Implementation Scheme 57: The method of any one of claims 37 to 56, wherein the bispecific antibody is administered at least 4 times, at least 8 times, at least 12 times, at least 16 times, at least 20 times, at least 24 times, at least 28 times, or at least 32 times.
[0183] Implementation Scheme 58: The method of any one of claims 37 to 57, wherein the anti-PD1 or PD-L1 antibody is nivolumab, pembrolizumab, simipremab, dostalimumab, riverimab, toripalimab, tislelizumab, camrelizumab, sintilimab, penaprilimab, cepalimumab, slulilimumab, putelilimumab, fenolinumab, atezolizumab, durvalumab, avelumab, cosilimumab, suglilimumab, envorimab, adebenone, socazolimumab, or tagorimab.
[0184] Implementation Scheme 59: The method of claim 58, wherein the anti-PD1 or PD-L1 antibody is administered at a dose of about 100 mg to about 1800 mg.
[0185] Implementation Scheme 60: The method of claim 59, wherein the anti-PD1 or PD-L1 antibody is administered in a dose of about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 800 mg, about 1000 mg, about 1200 mg, about 1500 mg, or about 1800 mg.
[0186] Implementation Scheme 61: The method of any one of claims 37 to 60, wherein the anti-PD1 or PD-L1 antibody is administered in liquid formulation form.
[0187] Implementation Scheme 62: The method of any one of claims 37 to 61, wherein the anti-PD1 or PD-L1 antibody is administered via intravenous infusion.
[0188] Implementation Scheme 63: The method of any one of claims 37 to 62, wherein the anti-PD1 or PD-L1 antibody is administered at approximately every 2 weeks, approximately every 3 weeks, approximately every 4 weeks, or approximately every 6 weeks.
[0189] Implementation Scheme 64: The method of claim 63, wherein the anti-PD1 or PD-L1 antibody is administered at least 4, 8, 12, 16, 20, 24, 28, or 32 times.
[0190] Implementation Scheme 65: The method of any one of claims 37 to 64, wherein the bispecific antibody and the anti-PD1 or PD-L1 antibody are administered simultaneously.
[0191] Implementation Scheme 66: The method of any one of claims 37 to 64, wherein the bispecific antibody and the anti-PD1 or PD-L1 antibody are administered sequentially.
[0192] Implementation Scheme 67: The method of claim 58, wherein the anti-PD1 or PD-L1 antibody is pembrolizumab.
[0193] Implementation Scheme 68: The method of claim 58, wherein the anti-PD1 or PD-L1 antibody is pterolimab.
[0194] Implementation Scheme 69: The method of claim 67 or 68, wherein the anti-PD1 antibody is administered at a dose of about 200 mg.
[0195] Implementation Scheme 70: The method of any one of claims 67 to 69, wherein the anti-PD1 antibody and the bispecific antibody are administered simultaneously.
[0196] Implementation Scheme 71: The method of claim 70, wherein the bispecific antibody and the anti-PD1 antibody are administered in liquid formulation.
[0197] Implementation Scheme 72: The method of claim 71, wherein the liquid formulation is administered via intravenous infusion.
[0198] Implementation Scheme 73: The method of any one of claims 37 to 72, wherein the cancer is a solid tumor.
[0199] Implementation Scheme 74: The method of claim 73, wherein the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, bile duct cancer, melanoma, or colorectal cancer.
[0200] Implementation Scheme 75: The method of claim 74, wherein the cancer is non-small cell lung cancer; optionally, wherein the cancer is locally advanced or metastatic.
[0201] Implementation Scheme 76: The method of any one of claims 37 to 75, wherein the cancer is a thermal tumor.
[0202] Implementation Scheme 77: The method of any one of claims 37 to 75, wherein the cancer is a cold tumor.
[0203] Implementation Scheme 78: The method of any one of claims 37 to 77, wherein the cancer is infiltrated by immune cells.
[0204] Implementation Scheme 79: The method of any one of claims 37 to 78, wherein the cancer is advanced or metastatic.
[0205] Implementation Scheme 80: The method of any one of claims 37 to 79, wherein the cancer is recurrent, drug-resistant, or refractory.
[0206] Implementation Scheme 81: The method of claim 80, wherein the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy.
[0207] Implementation Scheme 82: The method of any one of claims 37 to 81, wherein the subject is a human being.
[0208] Implementation Scheme 83: The method of claim 82, wherein the subject has received anti-PD-1 / PD-L1 treatment.
[0209] Implementation Scheme 84: The method of any one of claims 37 to 83, wherein the method (1) depletes tumor-infiltrating lymphocytes (TILs)-regulatory T cells (Treg cells) or Treg cells in the tumor microenvironment (TME); (2) increases cytokine levels in the TME; (3) enhances T cell proliferation and / or activity against the cancer; (4) enhances macrophage-mediated phagocytosis; (5) enhances dendritic cell-mediated antigen presentation; (6) reduces tumor immune escape; or any combination of (1)-(6).
[0210] Implementation Scheme 85: The method of any one of claims 37 to 84, wherein the method (1) selectively eliminates CTLA4 and CD47 positive cells by antibody-dependent cell-mediated cytotoxicity (ADCC); (2) has a low risk of triggering immune-related adverse events (irAEs); (3) has a low risk of triggering cytokine release syndrome (CRS); or (4) has reduced hematologic toxicity; or any combination of (1) to (4). Example
[0211] The following embodiments are for illustrative purposes only and are not intended to be limiting unless expressly stated otherwise. Therefore, the invention should not be construed as limited to the following embodiments, but should be construed as covering any and all variations that may be apparent from the teachings provided herein. Example 1: Antitumor activity of HX044
[0212] 1. In vivo MC-38-hCD47 humanized homologous model (HuGeMM): The MC38-hCD47 HuGeMM humanized homologous mouse model was constructed by knocking in the hCD47 gene (KI) into the mouse colon cancer cell line MC-38 and then inoculating this tumor cell line into hCTLA4 x hCD47 x hSIRPα HuGeMM mice. When the tumor reached approximately 70 mm... 3 Mice were randomly assigned to groups and treated accordingly. Different groups of mice were administered low, medium, or high doses of HX044, or a reference antibody / protein (ipilimumab and SIRPα-Fc), respectively. Treatment groups included HX044 (0.132, 1.98, and 6.6 mg / kg, IP twice weekly), SIRPα-Fc (0.092, 1.38, and 4.6 mg / kg, IP twice weekly), ipilimumab analogs (0.172, 2.58, and 8.6 mg / kg, IP twice weekly), and a carrier (PBS). All treatments were molecularly equivalent. Tumor volume was assessed twice weekly until the mean tumor volume reached 2000 mm. 3 Tumor growth inhibition (TGI) is calculated as TGI% = (1 - Vtreatment / Vcontrol) ×100.
[0213] like Figure 1 As shown, strong antitumor activity of HX044 was observed in HuGEMM mice (MC38-hCD47 model) with hCTLA4xhCD47xhSIRPα C57 / B6 background, which was significantly higher than either SIRPα-Fc or ipilimumab, especially at low dose levels (<0.2 mg / kg).
[0214] Furthermore, a combined study of HX044 and anti-PD-1 was conducted in mice carrying MC38 tumors. Specifically, MC38 mouse colorectal cancer cells were inoculated into the right posterior abdominal region of C57BL / 6J mice to form tumors. When the tumor volume reached approximately 50 mm... 3 Mice were randomly assigned to four groups and received the specified treatment as follows: vector, 10 mg / kg of HX044 mouse alternative antibody, 10 mg / kg of anti-mPD-1, or a combination of HX044 mouse alternative antibody and anti-mPD-1. All test substances were administered intraperitoneally twice weekly for two weeks. Tumor volume and body weight were measured three times weekly. Figure 5As shown, the antitumor efficacy of the HX044 alternative antibody combined with the anti-mouse PD-1 antibody was significantly superior to either single agent. These results indicate that the combined regulation of the PD-1 / PD-L1 axis and the CTLA-4 and CD47 checkpoint pathways can synergistically enhance antitumor immunity, thus supporting the possibility that combining HX044 with PD-1 / PD-L1 inhibitors (such as putelimab or pembrolizumab) can further improve antitumor efficacy.
[0215] 2. In vivo B16F10-hCD47 HuGeMM syngeneic mouse model: A humanized syngeneic mouse model of B16F10-hCD47 HuGeMM was constructed by knocking in the hCD47 gene (KI) into the mouse melanoma cell line B16F10 and then inoculating this tumor cell line into hCTLA4 x hCD47 x hSIRPα HuGeMM mice. When the tumor reached approximately 70 mm... 3 Mice were randomly assigned to groups and treated. Treatment groups included HX044 (3.3 mg / kg intraperitoneally twice, followed by 6.6 mg / kg four times), SIRPα-Fc (2.3 mg / kg intraperitoneally twice, followed by 4.6 mg / kg four times), ipilimumab analog (4.3 mg / kg intraperitoneally twice, followed by 8.6 mg / kg four times), and a carrier (PBS). All treatments were molecularly equivalent. Tumor volume was assessed twice weekly until a mean tumor volume of 2500 mm² was achieved. 3 Tumor growth inhibition (TGI) was calculated as TGI% = (1 - Vtreatment / Vcontrol) × 100. At the end of this experiment, tumors and spleens were collected from three mice in each group, and immune cells were analyzed using flow cytometry. reg Cells were sorted as CD3+CD4+Foxp3+ cells, helper T cells as CD3+CD4+Foxp3- cells, and cytotoxic T cells as CD3+CD8+Foxp3- cells.
[0216] like Figure 2 As shown, HX044 also exhibited strong antitumor activity in the B16F10-hCD47 melanoma model (traditional “cold” tumor) (5 mg / kg followed by 10 mg / kg), and was significantly higher than either ipilimumab or SIRPα-Fc.
[0217] In addition, such as Figure 3 As shown, an increase in TIL-T cells and TIL-T-related abnormalities were also observed in the tumors of the HX044-treated group. reg The decrease was significant, and the increase was much greater than that in the ipilimumab-treated group or the SIRPα-Fc-treated group. This observation indicates that TIL-T...reg The reduction in [something] also contributes to the antitumor activity of HX044. Example 2: Hematologic Toxicology of HX044
[0218] To evaluate the hematologic toxicology of HX044, hCTLA4 x hCD47 x hSIRPα HuGeMM C57BL / 6J mice were randomly assigned to groups based on body weight and administered HX044 (9.2 mg / kg intraperitoneally, twice weekly), SIRPα-Fc (6.4 mg / kg intraperitoneally, twice weekly), ipilimumab analogue (12 mg / kg intraperitoneally, twice weekly), or a carrier (PBS) for 2 weeks (5 doses in total). Grouping was designated as day 0. Hematologic analysis was performed on days 4 and 11. Whole blood samples were collected at the end of treatment (day 15) for lymphocyte composition analysis. reg Cells were sorted as CD3+CD4+Foxp3+ cells; helper T cells were sorted as CD45+CD4+Foxp3- cells; and cytotoxic T cells were sorted as CD45+CD8+Foxp3- cells.
[0219] As shown, peripheral T cells were observed in non-tumor-bearing HuGeMM mice treated with high doses. Figure 4 It is virtually non-toxic, indicating minimal adverse effects on lymphocyte composition and therefore minimal hematologic toxicity.
[0220] All in vivo mouse experiments were conducted under sterile conditions at the Crown Bioscience SPF facility and strictly in accordance with the National Institutes of Health's Guidelines for the Care and Use of Laboratory Animals. The protocols were approved by the Crown Bioscience IACUC Committee. Study designs followed the ARRIVE guidelines. Example 3: Pharmacokinetic (PK) Study of Crab-Eating Mammals
[0221] Crab-eating macaques were identified as the pharmacology-relevant species for assessing the human risks of HX044. In the PK study, cynomolgus macaques received a single intravenous infusion of HX044 at doses of 0.3 mg / kg, 1 mg / kg, or 3 mg / kg. The primary PK parameters (C...) were... max and AUC 0-last No significant gender differences were observed; systemic drug exposure (C max and AUC 0-last The pharmacokinetic profile of HX044 was positively correlated with dose level. HX044 exhibited linear pharmacokinetic characteristics in cynomolgus monkeys. Example 4: Toxicological Study of Crab-Eating Mammals
[0222] In toxicology studies, cynomolgus monkeys were repeatedly intravenously infused with undiluted HX044 at doses of 1, 6, and 40 mg / kg, once a week for four weeks (a total of five administrations), followed by a six-week recovery period. In the 40 mg / kg dose group, one animal died due to an infusion reaction, and another animal was euthanized due to electrolyte imbalance and malnutrition caused by prolonged diarrhea. Animals in the 1, 6, and 40 mg / kg dose groups showed decreased white blood cell and neutrophil counts, decreased erythrocyte-related markers (RBC, HGB, and HCT), increased reticulocyte counts, elevated C-reactive protein (CRP), and decreased thymocyte density. Animals in the 6 and 40 mg / kg dose groups showed decreased albumin (Alb), increased UREA, decreased CD3-CD20+, decreased complement, increased bone marrow (sternal) cell density, and decreased adipocytes. Animals in the 40 mg / kg dose group showed increased Glb and IgG, decreased cortical cell density in lymph nodes (mesenteric, inguinal, and mandibular), and diffuse mononuclear cell hypertrophy or infiltration in the portal and central lobules of the liver. No significant effects on the cardiovascular, central nervous, or respiratory systems were observed.
[0223] Therefore, under the conditions of this study, the highest non-serious toxic dose (HNSTD) is 6 mg / kg. The estimated human equivalent dose is approximately 2 mg / kg, and the maximum recommended starting dose is 0.33 mg / kg (1 / 6 × 2 mg / kg). Accordingly, the starting dose for the Phase I trial of HX044 was determined to be 0.1 mg / kg. Example 5: Phase I / IIa First-in-Human Study of HX044 in Patients with Advanced Solid Tumors
[0224] This study comprises a Phase I dose-escalation portion and a Phase IIa dose-extension portion to determine the maximum tolerated dose (MTD) and / or recommended Phase II dose (RP2D), and to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of HX044. Phase I includes a staggered dose-escalation design for both HX044 monotherapy and HX044 in combination with patelimab. The study is divided into a screening period (28 days before first administration), a treatment period (maximum 24 months), a safety follow-up period, and a survival follow-up period.
[0225] Purpose and endpoint:
[0226] Phase I: Dosage escalation phase
[0227] Phase IIa: Dose Extension Phase
[0228] Abbreviations: ADAs, Anti-drug antibodies; AUC 0-t The area under the concentration-time curve from 0 to a specific time; C trough Trough concentration before administration; CL, clearance rate; C max Maximum drug concentration; DCR, disease control rate; DLT, dose-limiting toxicity; DOR, duration of response; iRECIST, criteria for evaluating immune response in solid tumors (revised RECIST 1.1 for immunotherapy); mOS: median overall survival; mPFS: median progression-free survival; MTD, maximum tolerated dose; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RECIST 1.1, criteria for evaluating efficacy in solid tumors version 1.1; RP2D, recommended phase II dose; t 1 / 2 Effective terminal elimination half-life; T max Time to reach maximum drug concentration; V d Apparent volume of distribution; V ss Steady-state distributed volume.
[0229] Study population:
[0230] Phase I enrollment will be limited to approximately 60 participants, while Phase IIa enrollment will be limited to approximately 100 participants from 3 to 5 selected tumor type cohorts. Participants must meet the following criteria to be eligible for inclusion in this study:
[0231] (1) Age 18 to 75 (inclusive);
[0232] (2) The Eastern Cooperative Oncology Group (ECOG) performance status score was 0 to 1;
[0233] (3) Advanced malignant solid tumors confirmed by cytology or histology:
[0234] Phase I includes subjects with advanced malignant solid tumors that are refractory or relapsed to standard therapy, or subjects for whom no effective standard therapy is available, or subjects who refuse standard therapy, regardless of prior PD-1 / PD-L1 exposure.
[0235] Stage IIa includes two groups of subjects with histologically or cytologically confirmed locally advanced (Stage IIIB / IIIC, unsuitable for radical surgery and / or radiotherapy, regardless of concurrent / sequential chemotherapy) or metastatic (Stage IV) NSCLC, who have previously received PD-1 / PD-L1 inhibitor therapy (with or without chemotherapy), and for whom PD-L1 expression is not restricted. Cohort A includes HX044 monotherapy, and Cohort B includes HX044 in combination with patelimab. Cytology is only performed when tissue samples are unavailable (e.g., patients cannot tolerate biopsy); if the primary lesion is histologically confirmed, cytology results from metastatic lesions may be accepted after imaging (e.g., PET-CT) has ruled out benign disease. Subjects unsuitable for PD-1 / PD-L1 inhibitor therapy are also permitted to enroll.
[0236] (4) According to RECIST v1.1, at least one measurable tumor is required (patients with no measurable lesions but evaluable tumor lesions are allowed in the first two dose levels of stage I; at least one measurable tumor lesion must be present in stage IIa).
[0237] Research drug:
[0238] HX044 (produced by Nanjing Pubo Biotechnology Co., Ltd.): Clear, colorless to pale yellow liquid, 50mg:5ml / bottle.
[0239] Putelimab Injection (Puyouheng) ® Produced by Dingkang (Wuhan) Biopharmaceutical Co., Ltd.: Colorless to pale yellow, slightly opalescent to mildly opalescent liquid, 100mg:10ml / bottle.
[0240] Administration:
[0241] Intravenous infusion: HX044 was infused over 90 minutes at a constant infusion rate in a 0.9% sodium chloride infusion bag. Putelimab was diluted with 0.9% sodium chloride to a final concentration of 1.0–10 mg / mL and infused over 60 minutes (±15 min).
[0242] Treatment plan:
[0243] Phase I: Dosage escalation phase
[0244] HX044 Single Drug Dosage Escalation Cohort
[0245] Subjects received HX044 via intravenous infusion (IV) every 3 weeks (21±3 days). Accelerated titration was used, followed by a conventional 3+3 dose escalation method. One subject was enrolled at each of the 0.1 mg / kg and 0.5 mg / kg doses. If a single subject experienced a DLT or ≥G2-related adverse event (AE) during the DLT observation period, the cohort reverted to the conventional 3+3 design.
[0246] Planned dose levels (intermediate dose levels may be explored based on decisions made during the safety review):
[0247] 0.1 mg / kg: 1 subject
[0248] 0.5 mg / kg: 1 subject
[0249] 1.0 mg / kg: 3 to 6 subjects
[0250] 2.0 mg / kg: 3 to 6 subjects
[0251] 4.0 mg / kg: 3 to 6 subjects
[0252] 8.0 mg / kg: 3 to 6 subjects
[0253] 15.0 mg / kg: 3 to 6 subjects
[0254] 25.0 mg / kg: 3 to 6 subjects
[0255] Accelerated titration stage:
[0256] A single-case cohort was used until an adverse event associated with the study drug (AE) of DLT or ≥G2 was observed during the DLT observation period (cycle 1), at which point the dose escalation reverted to the traditional 3+3 design.
[0257] The first subject was given an initial dose of 0.1 mg / kg and received a maximum of one cycle of study treatment. If no significant safety concerns were identified at the end of the DLT period, the next subject could be initiated at a dose level of 0.5 mg / kg.
[0258] Traditional 3+3 stage:
[0259] Once a DLT or ≥G2-related adverse events associated with the study drug are observed, the single-case accelerated titration phase is terminated. The study follows the traditional 3+3 dose escalation protocol, with at least 3 subjects enrolled sequentially in each cohort at escalating doses.
[0260] HX044 and PD-1 Putelimab Injection (Puyouheng) ® Combined dose escalation cohort
[0261] Ptelimab injection will be administered intravenously at a fixed dose of 200 mg every 3 weeks (Q3W) over 60 minutes (±15 minutes). A staggered dose-escalation study design combined with the traditional “3+3” dose-escalation algorithm will be used to determine the MTD and / or recommended dose. The planned starting dose of HX044 is 2.0 mg / kg (or 4.0, 8.0 mg / kg based on updated monotherapy data). Enrollment will begin in the combination therapy escalation cohort at the corresponding dose level after the SRC confirms that the monotherapy group can be escalated to the next dose level. In other words, combination therapy is permitted at the corresponding dose level after HX044 monotherapy has been escalated to 2, 4, 8, 15.0, and 25.0 mg / kg. Intermediate dose levels may be explored based on decisions made during the safety review. The starting dose for combination therapy dose escalation will be determined based on available data from HX044 monotherapy dose escalation.
[0262] Planned dose level:
[0263] HX044 2.0 mg / kg and putelimab 200 mg: 3 to 6 subjects
[0264] HX044 4.0 mg / kg and patelimab 200 mg: 3 to 6 subjects
[0265] HX044 8.0 mg / kg and patelimab 200 mg: 3 to 6 subjects
[0266] HX044 15.0 mg / kg and patelimab 200 mg: 3 to 6 subjects
[0267] HX044 25.0 mg / kg and patelimab 200 mg: 3 to 6 subjects
[0268] In both the monotherapy and combination dose escalation cohorts, subjects received HX044 via intravenous infusion (IV) every 3 weeks (21 ± 3 days). Dose escalation continued until the MTD was determined or the maximum dose was reached.
[0269] In each dose escalation cohort, the first three subjects received HX044 at least 24-hour intervals.
[0270] The dose escalation continues as follows:
[0271] If none of the three subjects in a given dose group develops DLT, three new subjects will be enrolled in the next escalation dose cohort. The original subjects may continue to receive the original dose.
[0272] - If one of the first three subjects in a dose cohort develops a dose-limiting lesion (DLT) within 21 days of the first dose, three additional subjects are added to that dose cohort. If none of the three additional subjects develop a DLT, three new subjects can be enrolled in the next dose escalation cohort. If one or more of the three additional subjects develop a DLT, the mean time to dose (MTD) has been exceeded, and dose escalation is terminated.
[0273] - If two or more of the first three subjects in a dose cohort develop DLT within 21 days after the first dose, the MTD has been exceeded and dose escalation is terminated.
[0274] - If the MTD is exceeded, the previous lower dose cohort (or a new dose to be explored jointly by the SRC) is used to determine the MTD. If the dose cohort has fewer than 6 subjects, it can be increased to a total of 6 subjects. If fewer than 2 out of the 6 subjects develop DLT (i.e., less than one-third), that dose is the MTD.
[0275] - If the dose is increased to 25 mg / kg (maximum dose) and the MTD has not been reached, the SRC shall decide whether to continue increasing the dose.
[0276] Dosage escalation continues until MTD is identified or the maximum dose is reached.
[0277] Dose-limiting toxicities (DLTs) were assessed from the first dose of study treatment (day 1) until 21 days later (day 22). MTD was defined as the incidence of DLTs at the highest dose level in a given cohort that was less than 33% (one-third) of the total dose level.
[0278] The SRC will evaluate available study data during the trial (including PK data available at the time of decision-making) to determine whether to proceed to the next dose level during the dose escalation phase, or to determine whether to adjust the escalation dose based on the data obtained. RP2D is directly recommended by the SRC based on existing aggregated study data. In-subject dose escalation is permitted.
[0279] Phase IIa: Dose Expansion Phase
[0280] Phase IIa therapy will enroll up to 100 patients with advanced solid tumors from 3 to 5 selected tumor types. Cohort A and Cohort B will be established, each enrolling up to 30 patients with advanced NSCLC who have failed prior PD-1 / PD-L1 therapy, to evaluate the preliminary efficacy and safety of HX044 monotherapy or in combination with putelimab.
[0281] Cohort A includes patients with advanced NSCLC who have failed prior PD-1 / PD-L1 therapy and received HX044 monotherapy. Cohort B includes patients with advanced NSCLC who have failed prior PD-1 / PD-L1 therapy and received HX044 in combination with patelimab. Other selected tumor cohorts will be added based on data available in Phase I.
[0282] Subjects received HX044 monotherapy or HX044 in combination with patelimab every 3 weeks (21±3 days) according to RP2D. Study treatment continued every 3 weeks (21±3 days) until intolerable toxicity, withdrawal of informed consent, disease progression, death, loss to follow-up, initiation of new antitumor therapy, or study treatment duration of 24 months, whichever occurs first.
[0283] Figure 5 A schematic diagram of the Phase I and Phase IIa trials is shown. Figure 6 A schematic diagram of the accelerated titration stage and the traditional 3+3 stage is shown.
[0284] Evaluate:
[0285] Safety was assessed throughout the study period up to 90 (±7) days after the last study treatment. All TEAEs were pooled by incidence, highest NCI CTCAE V5.0 grade, and worst correlation with the study treatment.
[0286] Blood samples were collected at fixed time intervals for pharmacokinetic (PK) and immunogenicity assessment. Serum pharmacokinetic analyses of HX044 and patelimab (if applicable) were performed using a non-compartmental model method with validated Phoenix WinNonlin® software (version 8.4 or later, Certara, USA). The pharmacokinetic sampling time points for the HX044 monotherapy / combination escalation phases are shown in the table below:
[0287] Abbreviations: C, cycle; D, day; EOI, end of infusion; PK, pharmacokinetics.
[0288] The pharmacokinetic sample time points for the extended-phase combination therapy of HX044 and patelimab are shown in the table below:
[0289] Abbreviations: C, cycle; D, day; EOI, end of infusion; PK, pharmacokinetics.
[0290] Anti-drug antibodies against HX044 and patelimab injection were assessed using a validated assay (electrochemiluminescence immunoassay). To minimize subject burden, blood collection times were typically aligned with PK collection times: cycles 1, 2, 3, 4, 5, 6, 10, 14, and 18, followed by every 8 cycles; Day 1: within 60 minutes before the start of infusion. Unplanned immunogenic blood samples should be collected as soon as possible on the day the subject discontinues study treatment, or on the day of infusion-related reaction (IRR) or serious adverse event (SAE).
[0291] Tumor assessments used to evaluate efficacy (including best overall response rate, objective response rate (ORR), disease control rate (DCR) at 6 months and 12 months, duration of response (DOR), progression-free survival (PFS), and overall survival (OS)) were performed every 6 weeks (±7 days) during the first 12 months of treatment and every 12 weeks (±7 days) during the next 12 months until confirmed disease progression or death, treatment / study termination, loss to follow-up, initiation of new tumor therapy, or study completion / closure (whichever occurs first), and were performed during the survival follow-up period. This assessment was performed by the investigator using enhanced computed tomography (CT) or magnetic resonance imaging (MRI) and scored according to the Recognition of Efficacy in Solid Tumors Version 1.1 [RECIST 1.1] and the Immune RECIST [iRECIST] (partial response and / or complete response). Patients who discontinue study treatment for reasons other than disease progression should continue to undergo imaging evaluation every 12 weeks (±7 days) until disease progression, death, loss to follow-up, study completion / closure, initiation of new anti-tumor therapy, or for a maximum of 12 months (whichever occurs first).
[0292] Analyst population:
[0293] The analysis set is defined in the table below:
[0294] Abbreviations: AUC, Area Under the Plasma Concentration-Time Curve; C max Maximum plasma concentration; ICF (Informed Consent Form); PK (Pharmacokinetics).
[0295] Preliminary results:
[0296] To date, 19 patients have been enrolled at dose levels of 0.1, 0.5, 1.0, 2.0, 4.0, 8.0, and 10.0 mg / kg. All cohorts at 0.1 to 8.0 mg / kg completed the dose-limiting toxicity (DLT) observation period without any observed DLTs, indicating good tolerability of HX044 within this range. Of the 13 patients who underwent at least one post-baseline imaging assessment, one patient with renal cell carcinoma at the 4.0 mg / kg dose level achieved partial response (PR), and five patients achieved stable disease (SD): two at 1.0 mg / kg (one with gastric cancer and one with head and neck squamous cell carcinoma, respectively), one at 2.0 mg / kg (cholangiocarcinoma), one at 4.0 mg / kg (lung adenocarcinoma), and one at 8.0 mg / kg (colon cancer). These efficacy results demonstrate that HX044 exhibits clinical activity from the explored dose levels. References
[0297] The following publications are incorporated herein by reference in their entirety: 1. Zhang et al., Sci Transl Med, 2021, 13(605): eabg8693. 2. Ptolemab Injection Instructions, Lepu Biopharma Ltd, 2022. 3. Zhang et al., Cell Rep Med, 2023, 4(12):101301. 4. Saber et al. Regul Toxicol Pharmacol. 2016;81:448–456. 5. Buchbinder et al., Am J Clin Oncol, 2016, 39:98–106. 6. Topalian et al., Cancer Cell, 2015, 27:450–461. 7. Willsmore et al., Eur J Immunol, 2021, 51:544–556. 8. Hui et al., Science, 2017, 355:1428–1433. 9. Das et al., J Immunol, 2015, 194:950–959. 10. Rupp et al., Transl Oncol, 2022, 20:101405. 11. Zhou et al., J Clin Invest, 2022, 132(16):e161065. 12.Du et al., Cell Res, 2018, 28(4):433–447. 13. Curran et al., PNAS, 2010, 107(9):4275–4280. 14. Wei et al., Cell, 2017, 170:1109–1119. 15. Wei et al., PNAS, 2019, 116:22699–22709. 16. Geels et al., Cancer Cell, 2024, 42(6):1051–1066.e7. 17. Tseng et al., PNAS, 2013, 110(27):11103–11108. 18. Liu et al., Nat Med, 2015, 21(10):1209–1215. 19.Soto-Pantoja et al., Cancer Res, 2014, 74(23):6771–6778. 20. Sockolosky et al., PNAS, 2016, 113(19):E2646–E2654. 21. Kauder et al., PLoS One, 2018, 13(8):e0201832. 22. Hellmann et al., N Engl J Med, 2019, 381(21):2020–2031. 23. Paz-Ares et al., Lancet Oncol, 2021, 22(2):198–211. 24. Socinski et al., J Clin Oncol, 2023, 41: TPS9146. 25.Rolfo et al., J Clin Oncol, 2020, 38:TPS3159. 26. He et al., J Clin Oncol, 2023, 41:9024. 27. BioNTech and OncoC4 presented positive Phase 1 / 2 data for their antibody candidate BNT316 / ONC-392 in refractory NSCLC at ASCO. Press Release. BioNTech SE. June 2, 2023. Accessed June 27, 2023. https: / / www.globenewswire.com / news-release / 2023 / 06 / 02 / 2681039 / 0 / en / BioNTech-and-OncoC4-Present-Positive-Phase-1-2-Data-for-Antibody-Candidate-BNT316-ONC-392-in-Hard-to-Treat-NSCLC-at-ASCO.html 28. OncoC4 announces that the U.S. FDA has granted Fast Track designation to ONC-392 as monotherapy for PD(L)1-resistant NSCLC. Press release. OncoC4. April 26, 2022. Accessed June 28, 2023. https: / / www.globenewswire.com / en / news-release / 2022 / 04 / 26 / 2429043 / 0 / en / OncoC4-Announces-Fast-Track-Designation-Granted-by-the-US-FDA-for-ONC-392-Monotherapy-in-PD-L-1-Resistant-NSCLC.html 29. Xiong et al., Lancet, 2025, 405(10481):839–849. 30. Lakhani et al., Lancet Oncol, 2021, 22(12):1740–1751. 31. Bray et al., CA Cancer J Clin, 2024. 32. Zhang et al., Cell Mol Immunol, 2020, 17(8): 807–821. 33. Zhang et al., Journal for ImmunoTherapy of Cancer, 2023;11:e006555. 34. Ecker et al., MAbs, 2015, 7(1): 9–14. 35. Ulrich et al., MAbs, 2017, 9(2): 182–212. 36.FDA Bispecific Antibody Development Programs Final Guidance[J]. 37. Pooya et al., Front Immunol, 2023, 14: 1155778. 38. Eladl et al., J Hematol Oncol, 2020, 13(1): 96. 39. Chen et al., Oncol Res, 2023, 32(1): 49–60. 40. Zhang et al., Sci Transl Med, 2021, 13(605): eabg8693. 41. Gao et al., Lancet Oncol. 2023. 24(10): 1134–1146. 42. Zhao et al., Lung Cancer. 2023. 184: 107355. 43. Ma et al., J Immunother Cancer. 2023. 11(6): e006654. 44. Xiong et al. Eur J Cancer. 2023. 190: 112936. 45. Son et al., Front Immunol. 2022 Nov 11;13:1027235. 46. Working Group of the Resuscitation Council. Emergency treatment of anaphylactic reactions: a guide for healthcare providers. 2012. [https: / / www.resus.org.uk / anaphylaxis / emergency-treatment-of-anaphylactic-reactions / Accessed 2019 Mar 14].
[0298] All publications and patents referenced in this specification are incorporated herein by reference as if each individual publication or patent were expressly and individually indicated to be incorporated herein by reference, and are incorporated herein by reference to disclose and describe the methods and / or materials associated with the referenced publications. References to any publication refer only to its disclosure prior to the filing date and should not be construed as an admission that the invention is not entitled to a prior art invention prior to that publication. Furthermore, the publication date provided may differ from the actual publication date, which may require independent verification. * * *
[0299] Although the foregoing invention has been described in considerable detail by way of illustration and examples for the purpose of clear understanding, it will be readily understood by those skilled in the art, based on the teachings of the invention, that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
[0300] Therefore, the foregoing only illustrates the principles of the invention. Those skilled in the art will understand that, although not explicitly described or shown herein, various arrangements embodying the principles of the invention and encompassing its spirit and scope can be conceived. Furthermore, all examples and conditional language used herein are primarily intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to advance the art, and should be interpreted as not constituting limitation on these specifically stated examples and conditions. Moreover, all statements herein recounting the principles, aspects, and embodiments of the invention, as well as specific examples thereof, are intended to cover their structural and functional equivalents. Additionally, the equivalents are intended to include both currently known equivalents and those developed in the future, i.e., any element developed to perform the same function, regardless of its structure. Furthermore, nothing disclosed herein is intended to be offered to the public domain, whether or not such disclosure is expressly stated in the claims.
Claims
1. A method for treating cancer in a subject of need, comprising administering to the subject a therapeutically effective amount of an anti-CTLA4 / CD47 bispecific antibody; wherein, The bispecific antibody comprises: (i) a light chain variable region domain (VL) and a heavy chain variable region domain (VH), the amino acid sequences of which have at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NOs:7 and 8, respectively, and the VL / VH specifically binds to human CTLA4; and (ii) a CD47 binding domain, the amino acid sequence of which has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:9; and wherein the bispecific antibody is administered at a dose of about 0.1 mg / kg to about 25.0 mg / kg, based on the subject's weight.
2. The method of claim 1, wherein (i) the VL and VH have amino acid sequences of SEQ ID NOs:7 and 8, respectively; and (ii) the CD47 binding domain has an amino acid sequence of SEQ ID NO:
9.
3. The method of claim 1 or 2, wherein the bispecific antibody comprises: (1) A first peptide chain (C1) comprising the VL and a light chain constant region (CL); (2) a second peptide chain (C2) comprising the VH and a heavy chain constant region (CH); and (3) a third peptide chain (C3) comprising the CD47 binding domain and the Fc region.
4. The method of claim 3, wherein (1) the amino acid sequence of C1 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:51; (2) the amino acid sequence of C2 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:52; and (3) the amino acid sequence of C3 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:
53.
5. The method of claim 4, wherein C1, C2 and C3 have amino acid sequences of SEQ ID NOs:51, 52 and 53, respectively.
6. The method of any one of claims 1 to 5, wherein the bispecific antibody is administered at a dose of about 0.1 mg / kg to about 8.0 mg / kg, about 1.0 mg / kg to about 8.0 mg / kg, about 1.0 mg / kg to about 15.0 mg / kg, about 1.0 mg / kg to about 25.0 mg / kg, about 2.0 mg / kg to about 8.0 mg / kg, about 2.0 mg / kg to about 15.0 mg / kg, about 2.0 mg / kg to about 25.0 mg / kg, about 4.0 mg / kg to about 8.0 mg / kg, about 4.0 mg / kg to about 15.0 mg / kg, about 4.0 mg / kg to about 25.0 mg / kg, about 8.0 mg / kg to about 15.0 mg / kg, about 8.0 mg / kg to about 25.0 mg / kg, or about 15.0 mg / kg to about 25.0 mg / kg.
7. The method of claim 6, wherein the bispecific antibody is administered at a dose selected from the group consisting of about 0.1 mg / kg, about 0.5 mg / kg, about 1.0 mg / kg, about 2.0 mg / kg, about 4.0 mg / kg, about 8.0 mg / kg, about 10.0 mg / kg, about 12.0 mg / kg, 15.0 mg / kg, about 20.0 mg / kg, and about 25.0 mg / kg.
8. The method of claim 6, wherein the bispecific antibody is administered at a dose of about 2.0 mg / kg.
9. The method of claim 6, wherein the bispecific antibody is administered at a dose of about 4.0 mg / kg.
10. The method of claim 6, wherein the bispecific antibody is administered at a dose of about 8.0 mg / kg.
11. The method of claim 6, wherein the bispecific antibody is administered at a dose of about 10.0 mg / kg.
12. The method of claim 6, wherein the bispecific antibody is administered at a dose of about 12.0 mg / kg.
13. The method of claim 6, wherein the bispecific antibody is administered at a dose of about 15.0 mg / kg.
14. The method of claim 6, wherein the bispecific antibody is administered at a dose of about 20.0 mg / kg.
15. The method of claim 6, wherein the bispecific antibody is administered at a dose of about 25.0 mg / kg.
16. The method of any one of claims 1 to 15, wherein more than one dose of the bispecific antibody is administered.
17. The method of claim 16, wherein the bispecific antibody is administered at least 4, 8, 12, 16, 20, 24, 28, or 32 times.
18. The method of claim 16 or 17, wherein the bispecific antibody is administered at a dosing interval of approximately once every 3 weeks.
19. The method of any one of claims 1 to 18, wherein the bispecific antibody is administered in the form of a liquid formulation.
20. The method of any one of claims 1 to 19, wherein the bispecific antibody is administered via intravenous infusion.
21. The method of claim 20, wherein a single dose of the bispecific antibody is administered over a period of 60 to 120 minutes.
22. The method of claim 21, wherein a single dose of the bispecific antibody is administered within approximately 90 minutes.
23. The method of any one of claims 1 to 22, wherein the cancer is a solid tumor.
24. The method of claim 23, wherein the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, bile duct cancer, melanoma, or colorectal cancer.
25. The method of claim 23, wherein the cancer is non-small cell lung cancer; optionally, wherein the cancer is locally advanced or metastatic.
26. The method of any one of claims 1 to 25, wherein the cancer is a thermal tumor.
27. The method of any one of claims 1 to 25, wherein the cancer is a cold tumor.
28. The method of any one of claims 1 to 25, wherein the cancer is infiltrated by immune cells.
29. The method of any one of claims 1 to 28, wherein the cancer is advanced or metastatic.
30. The method of any one of claims 1 to 29, wherein the cancer is recurrent, drug-resistant, or refractory.
31. The method of claim 30, wherein the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy.
32. The method of any one of claims 1 to 31, wherein the subject is a person.
33. The method of claim 32, wherein the subject has received anti-PD-1 / PD-L1 treatment.
34. The method of any one of claims 1 to 33, wherein the method: (1) depletes tumor-infiltrating lymphocytes (TILs)-regulatory T cells (Treg cells) or Treg cells in the tumor microenvironment (TME); (2) increases cytokine levels in the TME; (3) enhances T cell proliferation and / or activity against said cancer; (4) enhances macrophage-mediated phagocytosis; (5) enhances dendritic cell-mediated antigen presentation; or any combination of (1)-(5).
35. The method of any one of claims 1 to 33, wherein the method: (1) selectively eliminates CTLA4 and CD47 positive cells by antibody-dependent cell-mediated cytotoxicity (ADCC); (2) has a low risk of triggering immune-related adverse events (irAEs); (3) has a low risk of triggering cytokine release syndrome (CRS); or (4) has reduced hematologic toxicity; or any combination of (1) to (4).
36. The method of any one of claims 1 to 35, further comprising administering a therapeutically effective amount of an anti-PD1 or PD-L1 antibody.
37. A method for treating cancer in a subject in need, comprising administering to the subject a therapeutically effective amount of an anti-CTLA4 / CD47 bispecific antibody and a therapeutically effective amount of an anti-PD1 or PD-L1 antibody.
38. The method of claim 37, wherein the bispecific antibody comprises: (i) a light chain variable region domain (VL) and a heavy chain variable region domain (VH), the amino acid sequences of which have at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NOs:7 and 8, respectively, and the VL / VH specifically binds to human CTLA4; and (ii) a CD47 binding domain, the amino acid sequence of which has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:
9.
39. The method of claim 37 or 38, wherein (i) the VL and VH have amino acid sequences of SEQ ID NOs:7 and 8, respectively; and (ii) the CD47 binding domain has an amino acid sequence of SEQ ID NO:
9.
40. The method of any one of claims 37 to 39, wherein the bispecific antibody comprises: (1) A first peptide chain (C1) comprising the VL and a light chain constant region (CL); (2) a second peptide chain (C2) comprising the VH and a heavy chain constant region (CH); and (3) a third peptide chain (C3) comprising the CD47 binding domain and the Fc region.
41. The method of claim 40, wherein (1) the amino acid sequence of C1 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:51; (2) the amino acid sequence of C2 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:52; and (3) the amino acid sequence of C3 has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity with SEQ ID NO:
53.
42. The method of claim 41, wherein C1, C2 and C3 have amino acid sequences of SEQ ID NOs: 51, 52 and 53, respectively.
43. The method of any one of claims 37 to 42, wherein the bispecific antibody is administered at a dose of about 0.1 mg / kg to about 25.0 mg / kg, based on the subject's weight.
44. The method of claim 43, wherein the bispecific antibody is administered at a dose of about 0.1 mg / kg to about 8.0 mg / kg, about 1.0 mg / kg to about 8.0 mg / kg, about 1.0 mg / kg to about 15.0 mg / kg, about 1.0 mg / kg to about 25.0 mg / kg, about 2.0 mg / kg to about 8.0 mg / kg, about 2.0 mg / kg to about 15.0 mg / kg, about 2.0 mg / kg to about 25.0 mg / kg, about 4.0 mg / kg to about 8.0 mg / kg, about 4.0 mg / kg to about 15.0 mg / kg, about 4.0 mg / kg to about 25.0 mg / kg, about 8.0 mg / kg to about 15.0 mg / kg, about 8.0 mg / kg to about 25.0 mg / kg, or about 15.0 mg / kg to about 25.0 mg / kg.
45. The method according to claim 43, wherein, The bispecific antibody was administered at a dose selected from the group consisting of about 0.1 mg / kg, about 0.5 mg / kg, about 1.0 mg / kg, about 2.0 mg / kg, about 4.0 mg / kg, about 8.0 mg / kg, about 10.0 mg / kg, about 12.0 mg / kg, about 15.0 mg / kg, about 20.0 mg / kg, and about 25.0 mg / kg.
46. The method of claim 43, wherein the bispecific antibody is administered at a dose of about 2.0 mg / kg.
47. The method of claim 43, wherein the bispecific antibody is administered at a dose of about 4.0 mg / kg.
48. The method of claim 43, wherein the bispecific antibody is administered at a dose of about 8.0 mg / kg.
49. The method of claim 43, wherein the bispecific antibody is administered at a dose of about 10.0 mg / kg.
50. The method of claim 43, wherein the bispecific antibody is administered at a dose of about 12.0 mg / kg.
51. The method of claim 43, wherein the bispecific antibody is administered at a dose of about 15.0 mg / kg.
52. The method of claim 43, wherein the bispecific antibody is administered at a dose of about 20.0 mg / kg.
53. The method of claim 43, wherein the bispecific antibody is administered at a dose of about 25.0 mg / kg.
54. The method according to any one of claims 37 to 53, wherein the bispecific antibody is administered in the form of a liquid formulation.
55. The method according to any one of claims 37 to 54, wherein the bispecific antibody is administered via intravenous infusion.
56. The method according to any one of claims 37 to 55, wherein the bispecific antibody is administered at a dosing interval of approximately once every 3 weeks.
57. The method according to any one of claims 37 to 56, wherein the bispecific antibody is administered at least 4 times, at least 8 times, at least 12 times, at least 16 times, at least 20 times, at least 24 times, at least 28 times, or at least 32 times.
58. The method according to any one of claims 37 to 57, wherein the anti-PD1 or PD-L1 antibody is nivolumab, pembrolizumab, simipremab, dostalimumab, riverimab, toripalimab, tislelizumab, camrelizumab, sintilimab, penaprilimab, cepalimumab, slulilimumab, putelilimumab, fenolinumab, atezolizumab, durvalumab, avelumab, cochilimumab, sugarymab, envorimab, adebenone, socazolimumab, or tagorizumab.
59. The method of claim 58, wherein the anti-PD1 or PD-L1 antibody is administered at a dose of about 100 mg to about 1800 mg.
60. The method of claim 59, wherein the anti-PD1 or PD-L1 antibody is administered in a dose of about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 800 mg, about 1000 mg, about 1200 mg, about 1500 mg, or about 1800 mg.
61. The method according to any one of claims 37 to 60, wherein the anti-PD1 or PD-L1 antibody is administered in liquid formulation form.
62. The method according to any one of claims 37 to 61, wherein the anti-PD1 or PD-L1 antibody is administered by intravenous infusion.
63. The method according to any one of claims 37 to 62, wherein the anti-PD1 or PD-L1 antibody is administered at approximately every 2 weeks, approximately every 3 weeks, approximately every 4 weeks, or approximately every 6 weeks.
64. The method of claim 63, wherein the anti-PD1 or PD-L1 antibody is administered at least 4 times, at least 8 times, at least 12 times, at least 16 times, at least 20 times, at least 24 times, at least 28 times, or at least 32 times.
65. The method according to any one of claims 37 to 64, wherein the bispecific antibody is administered simultaneously with the anti-PD1 or PD-L1 antibody.
66. The method according to any one of claims 37 to 64, wherein the bispecific antibody and the anti-PD1 or PD-L1 antibody are administered sequentially.
67. The method of claim 58, wherein the anti-PD1 or PD-L1 antibody is pembrolizumab.
68. The method of claim 58, wherein the anti-PD1 or PD-L1 antibody is pterolimab.
69. The method of claim 67 or 68, wherein the anti-PD1 antibody is administered at a dose of about 200 mg.
70. The method according to any one of claims 67 to 69, wherein the anti-PD1 antibody is administered simultaneously with the bispecific antibody.
71. The method of claim 70, wherein the bispecific antibody and the anti-PD1 antibody are administered in liquid formulation.
72. The method of claim 71, wherein the liquid formulation is administered via intravenous infusion.
73. The method according to any one of claims 37 to 72, wherein the cancer is a solid tumor.
74. The method according to claim 73, wherein the cancer is lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, bile duct cancer, melanoma, or colorectal cancer.
75. The method of claim 74, wherein the cancer is non-small cell lung cancer; optionally, wherein the cancer is locally advanced or metastatic.
76. The method according to any one of claims 37 to 75, wherein the cancer is a thermal tumor.
77. The method according to any one of claims 37 to 75, wherein the cancer is a cold tumor.
78. The method according to any one of claims 37 to 77, wherein the cancer is infiltrated by immune cells.
79. The method according to any one of claims 37 to 78, wherein the cancer is advanced or metastatic.
80. The method according to any one of claims 37 to 79, wherein, The cancer is recurrent, drug-resistant, or refractory.
81. The method of claim 80, wherein the cancer is resistant or refractory to anti-PD-1 / PD-L1 therapy.
82. The method according to any one of claims 37 to 81, wherein the subject is a human being.
83. The method of claim 82, wherein the subject has received anti-PD-1 / PD-L1 treatment.
84. The method according to any one of claims 37 to 83, wherein the method (1) depletes tumor-infiltrating lymphocytes (TILs)-regulatory T cells (Treg cells) or Treg cells in the tumor microenvironment (TME); (2) increases cytokine levels in the TME; (3) enhances T cell proliferation and / or activity against said cancer; (4) enhances macrophage-mediated phagocytosis; (5) enhances dendritic cell-mediated antigen presentation; (6) reduces tumor immune escape, or any combination of (1)-(6).
85. The method according to any one of claims 37 to 84, wherein the method (1) selectively eliminates CTLA4 and CD47 positive cells by antibody-dependent cell-mediated cytotoxicity (ADCC); (2) has a low risk of triggering immune-related adverse events (irAEs); (3) has a low risk of triggering cytokine release syndrome (CRS); or (4) has reduced hematologic toxicity; or any combination of (1) to (4).
